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The inclusion of biologically-active ligands into organometallic complexes offers 
much scope for the design of novel drugs with enhanced, targeted activity. Studies on 
such complexes indicate that new mechanisms of action are possible when 
combining the bioactivity of the ligand with the properties inherent to the metal, 
leading to the possibility of overcoming current drug resistance pathways. This thesis 
is concerned with the synthesis and characterisation of ruthenium(II) and osmium(II) 
bis-arene complexes containing biologically-active ligands and their potential 
application as anticancer agents. Four groups of ligands are investigated: indole 
derivatives, aspartame, tamoxifen and flavonoids.  
Both indole derivatives studied resulted in the formation of complexes which were 
unstable, due to either polymerisation of the ligand or decomposition of the complex 
as a result of loss of the bound ligand with time. X-ray structural data obtained for 
[(6-p-cymene)Ru(6-1-methylindole-3-acetic acid)](PF6)2 revealed that the latter 
may be a result of partial loss of 6-coordination due to tilting of the indole ring away 
from the metal. 
Much more stable complexes were generated with aspartame, however the effect of 
the metal on the structure, electronics, acidity and decomposition of the ligand all 
resulted in the complexes being incapable of binding to and activating the human 
sweet taste receptor.   
Antiproliferative studies found that ruthenium and osmium complexes of tamoxifen 
were not active against hormone-dependent mcf-7 breast cancer cells although they 
were able to mimic the isolated ligand under certain conditions. Here, the inactivity 
 
ii 
is most likely a result of the organometallic fragment being too bulky to fit into the 
receptor active site. Although no cytotoxic activity was observed, evidence of 
intercalation of the complexes into DNA was obtained. 
Dual anticancer activity was discovered for two ruthenium complexes of flavonoids: 
[(6-p-cymene)Ru(6-flavanone)](PF6)2 and [(
6-biphenyl)Ru(6-flavanone)](PF6)2. 
Although the complexes are very similar in structure, the first displayed moderate 
cytotoxic activity against both A2780 and A549 cancer cells (IC50 30 – 40 µM), 
which may be a result of an observed DNA interaction, while the second was 
selectively highly cytotoxic towards A549 cancer cells (IC50 ~ 6 µM) and showed no 
evidence of targeting DNA. Moreover, antioxidant properties inherent to the ligands 
were found to be enhanced on metal binding, giving the complexes additional 
potential in applications for the prevention of cancer. 
Significantly, this work has identified the first anticancer active metal bis-arene 
complexes of biologically-active ligands, therefore demonstrating the validity of 
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1.1 Introduction 
This thesis is concerned with the synthesis and characterisation of ruthenium(II) and 
osmium(II) bis-arene complexes containing biologically-active ligands and their 
potential application as anticancer agents. A strong focus of this work involves 
investigating and understanding modifications to the ligand’s properties on metal 
binding, with a view to obtaining a greater chemical knowledge of such systems. 
This Chapter discusses metal-based drugs, previous work in the area of metal 
complexes of bioactive ligands, the comparative chemistries of ruthenium and 
osmium and the prospective biological interactions of metal bis-arene complexes. 
 
1.2 Metal-based Drugs 
Metal ions are often classed as ‘toxic’ or ‘non-toxic’, however their biological 
activity depends very much on speciation and it is now widely accepted that, with 
carefully controlled coordination chemistry, even ‘toxic’ metals can exhibit 
therapeutic properties[1]. It is also true that toxicity is concentration-dependent and 
elements considered to be biologically essential can be toxic at high doses (Bertrand 
Diagram[2], Figure 1.1). It is therefore very important to investigate and understand 
the effects of varying the oxidation state, numbers and geometries of coordinated 
ligands on the biological properties of metal complexes to design metal-based drugs 
with therapeutic properties at desired doses successfully[3]. 
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Figure 1.1 The Bertrand Diagram[2] representing the relationship between the 
therapeutic benefit of an element and its concentration. 
 
A number of metallic elements play crucial roles in biology and it is clear that many 
organic compounds used in medicine require metal ions for activation or 
biotransformation in order to achieve their mode of action. For example, 
haemoglobin which binds and delivers oxygen to body tissues requires an iron atom 
to function and calcium minerals are required in order for our bones to exist and 
grow. Electron-deficient metal centres attract electron rich biomolecules, such as 
proteins or DNA, leading to a high tendency for metal ions to bind to and interact 
with important biological targets. It is this extensive use of metal ions by nature 
which prompted inorganic chemists to investigate the potential of utilising metal 
complexes in medicinal applications[4]. 
Although research into metal-based drugs only began in the early 1900s, metal 
compounds have been used in medicine for thousands of years. The ancient 
Egyptians used copper to sterilise water, medicines containing gold were taken in 
China and Arabia around 2500 BC and zinc was used to aid the healing of wounds 
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cisplatin [cis-PtCl2(NH3)2] (Figure 1.2) by Barnett Rosenberg in the 1960s, which 
remains the world’s highest selling anticancer drug, that stimulated research into 
inorganic medicinal chemistry worldwide[5]. Since then, the versatility of metal-
based drugs has been illustrated by the design of a vast number of complexes for a 
wide range of therapeutic applications. For example; sodium nitroprusside is an iron-
based cardiovascular drug, the gold complex auranofin is used in the treatment of 
arthritis, silvadene (silver sulfadiazine) has antibacterial and antifungal properties 
and is used in the treatment of burns, bis(maltato)oxovanadium (BMOV) is an orally 
active insulin mimetic used to treat diabetes and Ceretec is a 99mTc(V) complex used 


















































Silvadene Ceretec BMOV  
Figure 1.2  Examples of metal-based drugs. The platinum anticancer drug cisplatin, 
sodium nitroprusside, auranofin, silvadene, BMOV and Ceretec.  
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1.3 Metal Anticancer Agents 
As illustrated in Section 1.2, metal complexes have a broad range of medicinal 
applications. Since those described in this thesis are assessed primarily for their 
potential to act as anticancer agents, a more detailed discussion of previous work in 
this area is presented. 
Cancer is a major cause of death worldwide[7]. It is the term used to describe over 
200 diseases which possess the common characteristic of uncontrolled cell division 
and the ability of these cells to invade healthy tissue. There are many approaches to 
the treatment of cancer depending on the form and stage of the disease, however 
there is a constant need for research into new drugs with novel mechanisms of 
action[7]. 
Following the discovery of cisplatin in 1969, there has been a vast expansion of 
research into the use of inorganic compounds in the treatment of cancer. Despite its 
success in the treatment of a wide range of cancers, cisplatin has a number of 
drawbacks which include toxicity and resistance[8]. This has led to the development 
of 2nd generation platinum drugs, such as carboplatin and oxaliplatin[9], which were 
found to have lower toxicity and are currently used for the treatment of ovarian and 
colon cancer, respectively[10]. Third generation compounds are also being explored, 
including the first orally active platinum drug, satraplatin (Figure 1.3), which is 
reduced in vivo and is currently undergoing clinical trials[11]. 
























Carboplatin SatraplatinOxaliplatin  
Figure 1.3  The chemical structures of the 2nd generation platinum anticancer agents 
carboplatin and oxaliplatin and the 3rd generation orally active drug satraplatin. 
 
There is also emerging literature regarding the use of non-toxic photoactivatable 
platinum(IV) complexes as pro-drugs which are activated by light to generate toxic 
platinum(II) species selectively at the target tumour site, thus reducing toxic side-
effects[12, 13]. Such complexes are currently being developed in research labs, two 
examples of which are shown in Figure 1.4. Both were found to be non-toxic (IC50 
value greater than 300 µM) to 5637 bladder cancer cells in the dark but when 
irradiated with light their toxicity dramatically increased with IC50 values of 49 and 
63 µM for cis,trans,cis-[Pt(N3)2(OH)2(NH3)2] and cis,trans-[Pt(N3)2(OH)2(en)], 
respectively (IC50 value = concentration of drug required to inhibit growth of cells by 
50%). They have also been shown to be active against a cisplatin-resistant cell line, 
indicating that the mechanism by which they kill cancer cells is different from that of 
cisplatin[1]. 
 















Figure 1.4 The chemical structures of cis,trans,cis-[Pt(N3)2(OH)2(NH3)2] and 
cis,trans-[Pt(N3)2(OH)2(en)], two photoactive platinum(IV) complexes which, on 
irradiation with light, become toxic to cells through generation of highly reactive 
platinum(II) species[1]. 
 
Ruthenium complexes have also received a lot of interest and are now studied 
intensively for their anticancer properties[14]. Ruthenium was seen as a promising 
metal due to its similar kinetics to platinum, on timescales comparable to cellular 
division processes[11], and its lower toxicity thought to be due to its ability to mimic 
iron and therefore bind to biomolecules such as serum albumin and transferrin[15]. 
Anticancer activity for ruthenium(III) complexes was first reported for Ru(III) 
ammines by Clarke, however they were too insoluble for use in the clinic[1].  Since   
then,  two of the most promising Ru(III) complexes are trans-
tetrachlorodimethylsulfoxideimidazoleruthenate(III) (NAMI-A) and trans-
tetrachlorobis(1H-indazole)ruthenate(III) (KP-1019) which have both entered 
clinical trials[16]. It is thought that such Ru(III) complexes act as prodrugs and are 
activated by reduction to Ru(II) in vivo to generate more labile complexes which can 
coordinate rapidly to biomolecules[14]. This led to increased efforts to study 
ruthenium(II) complexes, and of particular relevance to the work described in this 
thesis are the active organometallic ruthenium(II) mono-arene complexes.  
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Complexes of this type can be fine-tuned by varying the ligands to obtain desired 
pharmacological properties[17]. For example, [(6-THA)Ru(en)Cl]+  where THA = 
tetrahydroanthracene and en = ethylenediamine (Figure 1.5) has activity comparable 
to cisplatin with an IC50 value of 0.5 µM against A2780 human ovarian cancer cells 
(cisplatin IC50 = 0.6 µM)
[18]. It is interesting to note that osmium-arene analogues 






























Figure 1.5 The chemical structures of NAMI-A, KP1019 and [(6-THA)Ru(en)Cl]+. 
 
Although platinum and ruthenium have received the most interest in this area of 
research, it should be noted that many other metals have also been explored and 
some examples of these are shown in Figure 1.6[20, 21]. 
 




















Figure 1.6 The chemical structures of other metal complexes investigated for their 
potential as anticancer agents: titanocene dichloride, gold tetraphenylporphyrin and 
gallium maltolate. 
 
1.4 Metal Complexes of Biologically-Active Ligands 
In recent years, research into new pharmaceuticals, both organic and inorganic, has 
seen a change in trend away from cytotoxic compounds to molecular targeting 
agents[5]. This is particularly true for the treatment of cancer as there is a constant 
strive to overcome drug resistance by opening up new mechanisms of action[22].  
One approach which has shown rapid growth in recent years and a number of notable 
successes is the design of metal complexes incorporating biologically active ligands. 
Such compounds offer the possibility for design of metal-based drugs with enhanced, 
targeted activity by combining the specificity of the ligand to interact with a 
particular molecular site with the properties inherent to the metal centre. 
Consequently, there is a huge scope for design, attributable to the choice of metals 
available and the range of accessible oxidation states, number and type of additional 
coordinating ligands. This is turn allows the kinetics and thermodynamics of the 
complex to be controlled to a certain extent[23]. It is also true that the presence of the 
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metal could result in more efficient delivery of the active ligand to the target as the 
solubility, biodistribution and pharmacokinetics may be dramatically altered[22]. 
There are many examples of such complexes in the literature, incorporating a wide 
variety of biologically-active ligands such as amino acids[24], hormones[25], 
antimalarial drugs[26], inhibitors of resistance pathways[27] and non-steroidal anti-
inflammatory drugs[22] and with applications ranging from immunoassay tracers[25] to 
small molecule delivery agents[22]. There are also a number of non-medicinal 
applications such as catalysis and ‘supports’ for peptide synthesis[24]. A number of 
promising compounds in the field of cancer research have also been identified. These 
include cobalt complexes of nitrogen mustards, which show a 20-fold preference for 
hypoxic cancer cells over healthy cells[22] and perhaps most significantly, and of 
particular relevance to this work due to their organometallic nature, the Ferrocifen 
series of complexes (Figure 1.7) of the breast cancer drug tamoxifen. By replacing 
the phenyl group for a ferrocenyl centre, activity was found against both hormone 
independent and dependent breast cancer cells whereas tamoxifen is only active 
against the latter. These will be discussed in more detail in Chapter 5. 
 
 











Figure 1.7  The organometallic Ferrocifen series of complexes (right) derived from 
the purely organic breast cancer drug tamoxifen (left). 
 
1.5 Chemistry of Ruthenium and Osmium 
This thesis is concerned with organometallic complexes of ruthenium and osmium, 
therefore their comparative chemistries are briefly discussed. 
 
1.5.1 General 
Ruthenium and osmium are both group 8 transition metals positioned in the second 
and third row of the periodic table, respectively. They belong to a collection of 
metals classified as the ‘Platinum group’, which also consists of rhodium, palladium, 
iridium and platinum. All these metals have closely related physical and chemical 
properties and often occur together in the same mineral deposits. Osmium was 
discovered 41 years before its second row analogue, however much less is known 
about its chemistry[28]. This is most likely due to the higher cost of the metal and the 
greater difficulty associated with compound synthesis[29].  
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The two most common oxidation states of ruthenium, Ru(II) and Ru(III), are both 
substitutionally inert, although the latter to a greater extent. This makes ruthenium 
unique within the periodic table and is a feature which has proved useful for a 
number of single-electron transfer studies[30]. Third row transition metals are 
commonly more inert than those in the second and first rows and consistent with this, 
osmium is more inert than ruthenium, with ligand exchange rates around 105 times 
slower[31]. As a result of the lanthanide contraction, osmium is very similar in size to 
ruthenium, however due to its position in the third row, its outer 5d orbitals are 
highly exposed and hence sensitive to the electronic nature of coordinating ligands.  
Although osmium is found in a wider range of oxidation states than ruthenium (-2 to 
+8 compared to 0 to +8), this does not extend to coordination number. Apart from 
the most well-known osmium complex, osmium tetroxide (OsO4), the majority of 
complexes are low-spin octahedral[28]. In contrast to both ruthenium and iron, no 
characteristic cationic aqua ion [M(OH2)6]
3+/2+ species has been detected for 
osmium[31]. 
 
1.5.2 Ruthenium and Osmium in Medicine 
As discussed in Section 1.3, ruthenium compounds are suitable for use in biological 
applications due to their slow ligand exchange rates which are close to those of 
cellular processes and the capability of the metal to mimic iron in binding to specific 
biological molecules. An additional feature is that the oxidation states Ru(II), Ru(III) 
and Ru(IV) are accessible under physiological conditions, with reductants such as 
glutathione and ascorbate being capable of reducing Ru(III) and Ru(IV) and the 
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oxidation of Ru(II) readily induced by molecular oxygen or cytochrome oxidase[15]. 
The cytological stain, Ruthenium Red, [(NH3)5Ru-O-Ru(NH3)4-O-Ru(NH3)5]
6+, was 
the first compound of this metal to be used in biology[14]. Since then, numerous 
medicinal properties of the metal have been discovered including antimalarial, 
antimicrobial and anticancer, of which the latter has been covered in more detail in 
Section 1.3[15]. Furthermore, the radioactive nucleotide of ruthenium (97Ru) has 
shown promise as a radiopharmaceutical, with advantages over the currently widely 
used technetium alternative (99mTc) due to its longer half life allowing for more 
manipulation prior to use; however there are problems due to its lack of commercial 
availability[14]. 
Medicinal applications of osmium are much less common because it is generally not 
considered to be biologically relevant and in some forms can be highly toxic. 
However, some osmium complexes have been used for the treatment of rheumatoid 
arthritis in animals and anticancer activity has been reported for some Os(III) and 
Os(IV) neutral complexes[32, 33]. In addition, trypanocidal activity against T. b. brucei 
has been reported[34]. 
 
1.5.3 Organometallic Complexes 
Organometallic complexes of ruthenium and osmium are most common in lower 
oxidation states and contain ligands ranging from arenes, allyls and 
cyclopentadienyls to carbonyl, nitrido and cyano groups[29, 35, 36]. Since arene 
complexes form the basis of this research their chemistry will be briefly covered. 
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Ruthenium and osmium arene complexes exist as either mono- or bis-arene 
structures, commonly with the metal in either the zero or +2 oxidation state[29, 35]. 
 
1.5.3.1 Mono-Arene Complexes 
Ruthenium(II) and osmium(II) mono-arene complexes are known as ‘half-sandwich’ 
compounds with a pseudo octahedral ‘piano-stool’ structure, as shown in Figure 
1.8[37]. The η6-arene occupies three coordination sites (the ‘seat’), with the other 
ligands (X, Y and Z) at the remaining sites (the ‘legs’)[38]. These complexes possess 
stable metal-arene bonds, resulting in reduced tendency to oxidise to the +3 oxidation 
state[39, 40]. Due to the similarity in size of the two metals, the structures of mono-
arene complexes of osmium have been found to be very close to those of the 
ruthenium analogues with many bond lengths identical, however their chemistries 
have been shown to vary considerably[19, 41]. As a result of the interest in this class of 
complexes as anticancer drugs, extensive investigations[17, 19] into the effect of 
varying the arene[18, 38] and X[42, 43], Y, and Z[44-46] on the properties of the complexes 
have illustrated the extent to which exchange rates, structures, redox behaviour[47], 
solution-[48]and bio-chemistry[49, 50] are dependent on the ligands. The knowledge 
gained has allowed the design of complexes for specific applications. Although 
reports of the aqueous chemistry of Os(II) arene complexes are much more limited 
than for Ru(II)[19, 40], good solubility is generally observed for both metals[37, 39]. This 
is naturally dependent on the ligands involved and may become important in terms of 
tuning complexes for clinical applications. 
 








Figure 1.8  The general chemical structure of a half-sandwich metal mono-arene 
complex (M = Ru/Os). In applications as anticancer agents X is most often a halide 
and Y,Z is generally a chelating group with NN, NO or OO donor atoms. 
 
Ru(II) and Os(II) mono-arene structures with three non-equivalent ligands possess 
chirality, with a stereogenic centre at the metal. This gives rise to potential 
applications as asymmetric catalysts for a range of reactions, including alkene 
hydrogenation, Diels-Alder reactions and alkene metathesis[51, 52]. 
 
1.5.3.2 Bis-Arene Complexes 
Bis-arene Ru(II) and Os(II) sandwich complexes of the type shown in Figure 1.9, on 
which the work discussed in this thesis is based, may be synthesised from the 
appropriate chloride-bridged dimer, [(η6-arene)MCl2]2 (M = Ru/Os), by reaction with 
a silver salt in acetone (to remove bound chloride ligands) affording a mono-arene 
acetone intermediate. Reaction with a second arene in trifluoroacetic acid (TFA) 
yields the bis-arene structure[53, 54]. As for mono-arene complexes, bis-arene 
complexes are more highly documented for ruthenium. A search of the Cambridge 
crystallographic database (CCDC) revealed that while there are over 50 X-ray crystal 
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structures of ruthenium bis-arene complexes, only 2 such osmium structures have 
been reported. The stark contrast between these numbers and those for mono-arene 
complexes of ruthenium and osmium, of ca. 1600 and ca. 110 respectively, clearly 







Figure 1.9 The general chemical structure of a metal bis-arene complex (M = Ru/Os) 
 
1.5.3.3 Complexes with Bioactive Ligands 
Mono-arene complexes of ruthenium and osmium containing biologically-active 
ligands are known most frequently for amino acids and peptides where coordination 
to the metal is through -bonding via functional donor group atoms[24]. Bis-arene 
complexes are less common and significantly, there are no reported osmium bis-
arene complexes of biologically-active ligands. Nevertheless, there are a number of 
ruthenium examples including complexes of the essential amino acid 
phenylalanine[55] and derivatives of dopamine, a neurotransmitter which is important 
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in the regulation of many internal pathways[53] (Figure 1.10). Importantly, the 













Figure 1.10 The chemical structures of [(6-p-cymene)Ru(6-phenylalanine)]2+ [55] 
(left) and [(6-p-cymene)Ru(6-H-dopamine)]2+ [53] (right).  
 
1.6 Prospective Biological Interactions of Metal Bis-arene 
Complexes 
Metal complexes with the structures studied in this thesis have received very limited 
attention for potential applications as anticancer agents, although some work has 
been done which found them to possess good activity[56, 57]. In addition to the 
interesting properties the presence of the bioactive ligand will bring in the complexes 
studied in this thesis, a number of prospective biological interactions may be 
identified based on the physical and chemical properties of known metal bis-arene 
structures. Two such interactions which could lead to cytotoxicity to cancer cells are 
briefly discussed here to further illustrate the stimulation behind the research 
described in this thesis. 
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1.6.1 Accumulation in Mitochondria 
Mitochondria are central to cell function. They are involved in many processes such 
as; ATP synthesis, calcium uptake and release, pH control and DNA synthesis[58]. 
They are also considered to play a fundamental role in the regulation of programmed 
cell death (apoptosis)[59]. In response to certain stimuli, the outer membrane of the 
mitochondria becomes permeable, permitting soluble proteins such as cytochrome c 
to translocate to the intracellular region of the cell. These proteins are thought to 
activate caspases (signal transducing molecules) which in turn trigger cell death[59]. 
Mitochondria have been identified as important targets for the treatment of cancer[60], 
neurodegenerative diseases[61] and diabetes[62]. The targeting of mitochondria for the 
treatment of cancer offers the attractive possibilities of a novel mechanism of action, 
thus overcoming drug resistance and increasing the selectivity of drugs for cancerous 
over healthy cells[60].  
It has been shown that lipophilic cationic compounds, such as the complexes 
synthesised in this work, are attracted to the negatively charged internal 
transmembrane potential of mitochondria and accumulate within them as a 
consequence[60]. This potential has been shown to be approximately 60 mV more 
negative in cancerous cells (CX-1 colon carcinoma cells) than in healthy cells (CV-1 
monkey kidney epithelial cells), leading to a 10-fold preference of the compounds for 
the diseased cells. Once inside the mitochondria, the presence of the lipophilic 
cations is likely to interfere with cellular ATP production. This disruption to cell 
viability triggers the apoptotic pathway described above[63]. 
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A number of organic[63] and inorganic compounds have been investigated in this 
respect, of which the latter comprises mainly gold (I) complexes (e.g. Figure 1.11). 
These have been shown to induce mitochondrial swelling[58, 60, 64], a precursor event 
to mitochondrial membrane permeabilisation[59] and apoptosis. The complexes 
studied in this thesis are also lipophilic and cationic in nature and therefore have the 
















Figure 1.11 The chemical structure of a gold(I) carbene complex. An example of a 
lipophilic cationic metal complex capable of inducing mitochondrial swelling of 
carcinoma cells. 
 
1.6.2 DNA Bis-intercalators 
Intercalating agents are complexes which are able to insert between layers of base 
pairs on DNA. This disrupts the shape of the double helix which often results in 
unwinding of the helix. Such structural modifications can lead to inhibition of 
replication, transcription and DNA repair[65]. They are therefore attractive for the 
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treatment of cancer. Intercalators normally consist of at least one planar aromatic unit 
which is able to form stable hydrophobic stacking interactions with the bases on 
DNA. There are a number of examples of ruthenium[66] and osmium[67] complexes 
capable of intercalating into DNA via one of its ligands (Figure 1.12). The  crystal 
structure shown in Figure 1.13 illustrates how a similar rhodium complex inserts 




















Figure 1.12  The chemical structures of -[Ru(phenanthroline)3]
2+ [66] (left) and 
[Os(phenanthroline)2dppz]
2+ [67] (right). Both these complexes can intercalate into 
DNA. 
 
Figure 1.13 Crystal structure of -α-{Rh[(R,R)Me2trien]phi}
3+ (red) (trien = 
triethylenetetramine, phi = 9,10-phenanthrenequinone diimine) bound to the 
oligonucleotide double helix d(GTTGCAAC)2 (blue)
[68].  
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A search of the Cambridge Crystallographic Database reveals that bis-arene 
complexes of ruthenium and osmium have ligand-ligand distances in the range 3.34 
Å to 3.60 Å and 3.51 Å to 3.54 Å, respectively; however it should be noted that there 
are only two examples of the latter. The base-pair separation for the double-helical, 
B-form of DNA is 3.36 Å[69]. Since this value falls within the range for ruthenium 
bis-arene complexes (there are too few osmium examples to assume that they are a 
true representation of distances) it is theoretically possible to imagine such a 
complex with two extended aromatic ligands having the potential to act as a bis-
intercalator, with both ligands inserting themselves between DNA bases. Using the 
crystallographic data for a simple ruthenium bis-biphenyl complex[70], a model 
illustrating this mode of binding to a DNA double helix was created using Sybyl 
(Ver. 6.3, Tripos Inc.) software and is shown in Figure 1.14. This shows the 
ruthenium complex docked in the major groove with the two unbound biphenyl rings 
intercalating between bases. This model was created to illustrate that the relative 
distances make this type of interaction possible. No attempts were made to perform 
energy minimisation calculations.  
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Figure 1.14 Model of how a bis-arene metal complex [Ru(6-biphenyl)2]
2+ [70] might 
insert itself into the major groove of DNA resulting in bis-intercalation.  
 
To date the only reported examples of metal bis-intercalators involve two metal 
centres with a carbon linker[71-73]. Binding constants for ruthenium(II) complexes 
(e.g. Figure 1.15) have been found to be ca. 50 orders of magnitude greater than 
similar mono-intercalating complexes, exemplifying the increase in biological 
efficacy possible with multiple intercalation sites[73-75]. A similar increase in binding 
affinity could be envisaged with metal bis-arene structures over similar mono-arene 
complexes, leading to cytotoxic activity at far lower concentrations. 

























Figure 1.15 The chemical structure of [{Ru(dpq)2(µ-phen-5-S(CH2)2O(CH2)2S-5-
phen)]4+ (where dpq = dipyrido[3,2-d:2’,3’-f]quinoxaline, phen = 1,10-
phenanthroline and SOS = 2-mercaptoethylether), a flexible dinuclear ruthenium 
complex capable of bis-intercalation into DNA[73]. 
 
1.7 Aims 
The overall aim of this thesis is to synthesise and investigate the properties of novel 
unsymmetrical ruthenium(II) and osmium(II) bis-arene complexes incorporating 
biologically-active ligands. Four groups of ligands are investigated; indole 
derivatives, aspartame, tamoxifen and flavonoids. Through knowledge gained 
regarding the chemical and biological properties of the systems, the potential of such 
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Specific aims of this thesis are as follows. 
(1) Synthesise and characterise ruthenium and osmium bis-arene complexes 
containing a range of biologically-active ligands. 
(2) Probe the structure, solution chemistry and stability of the complexes. 
(3) Investigate and provide rational explanations for changes to ligand properties on 
binding to either metal centre. 
(4) Investigate the cancer cell cytotoxicity of the complexes and, if active, possible 
mechanisms of activity. 
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This chapter describes the main experimental techniques used in this work. More 
specific methods relating to individual experiments are described in the appropriate 
chapters. The synthesis and characterisation of the starting materials used for 
synthesis of the ruthenium and osmium complexes in subsequent chapters is also 
covered here. 
 
2.1 Synthesis of Starting Materials 
Ruthenium and osmium dimers of the form [(6-arene)MCl2]2 (M = Ru/Os, arene  = 
p-cymene/biphenyl) were used as starting materials for the synthesis of the bis-arene 
complexes studied in this thesis, therefore their preparations are described here. The 
methods closely follow previously reported procedures[1-3]. 
 
2.1.1 Materials 
RuCl3.xH2O was purchased from Precious Metals Online and OsCl3.xH2O from Alfa 
Aesar (x is assumed to be 3). –Terpenine was purchased from Sigma-Aldrich. 1,4-
Dihydrobiphenyl was prepared by a previously reported procedure[4]. Ethanol was 
dried by distilling over Mg/I2 prior to use. 
 
2.1.2 Preparation of Complexes 
[(
6
-p-cymene)RuCl2]2. RuCl3.xH2O (4.08 g, 0.02 mol) was dissolved in dry ethanol 
(120 mL) and following the drop-wise addition of -terpinene (20 mL, 0.15 mol) the 
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dark brown solution was heated under reflux at 368 K for 24 h. After cooling, the 
resulting red solution was filtered to give a deep red powder which was washed with 
ethanol and diethyl ether and dried overnight in vacuo. (Yield: 4.61 g, 75.3%).  
Anal. Found %C = 38.89; %H = 4.10. Calc. for C20H28Cl4Ru2 (M = 612.39): %C = 
39.23; %H = 4.61. 1H NMR, 600MHz (CDCl3):  1.30 (d, 12H), 2.16 (s, 6H), 2.95 




-biphenyl)RuCl2]2. RuCl3.xH2O (2.05 g, 0.01 mol) was dissolved in dry ethanol 
(120 mL) and following the addition of 1,4-dihydrophenyl (14.01 g, 0.09 mol) the 
dark brown solution was heated under reflux at 368 K for 24 h. After cooling, the 
solution, which had not significantly changed colour, was filtered to give a brown 
powder which was washed with ethanol and diethyl ether and dried overnight in 
vacuo. (Yield: 2.80 g, 85.7%).  
Anal. Found %C = 43.88; %H = 3.00. Calc. for C24H20Cl4Ru2 (M = 652.37): %C = 
44.19; %H = 3.09. 1H NMR, 600MHz (DMSO-d6):  6.13 (m, 6H), 6.44 (d, 4H), 




-p-cymene)OsCl2]2. OsCl3.xH2O (1.06 g, 0.003 mol) was dissolved in dry 
ethanol (75 mL) and following the drop-wise addition of -terpinene (5 mL, 0.04 
mol) the dark brown solution was heated under reflux at 368 K for 24 h. After 
cooling, the resulting orange solution was filtered to give a bright orange powder 
which was washed with ethanol and diethyl ether and dried overnight in vacuo. 
(Yield: 0.78 g, 65.3%).  
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Anal. Found %C = 30.73; %H = 3.65. Calc. for C20H28Cl4Os2 (M = 790.71): %C = 
30.38; %H = 3.57. 1H NMR, 500MHz (CDCl3):  1.32 (d, 12H), 2.21 (s, 6H), 2.80 




-biphenyl)OsCl2]2. OsCl3.xH2O (1.01 g, 0.003 mol) was dissolved in dry ethanol 
(75 mL) and following the addition of 1,4-dihydrobiphenyl (2.26 g, 0.015 mol) the 
brown solution was heated under reflux at 368 K for 24 h. After cooling, the 
resulting orange solution was filtered to give a dark orange powder which was 
washed with ethanol and diethyl ether and dried overnight in vacuo. (Yield: 1.04 g, 
88.1%).  
Anal. Found %C = 35.25; %H = 2.11. Calc. for C24H20Cl4Os2 (M = 830.69): %C = 
34.70; %H = 2.43. 1H NMR, 600MHz (DMSO-d6):  6.30 (t, 4H), 6.36 (t, 2H), 6.64 
(d, 4H), 7.45 (m, 6H), 7.71 (d, 4H). 
 
2.2 Nuclear Magnetic Resonance Spectroscopy[5-7] 
Nuclear magnetic resonance (NMR) spectroscopy is a powerful tool which can be 
used to probe the structure and properties of both organic and inorganic species.  The 
main nucleus studied in this thesis is 1H, although a few two-dimensional 
experiments were carried out using 13C. 1H NMR spectroscopy was utilised to 
characterise and explore the solution chemistry of the complexes synthesised. 
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2.2.1 Overview of Technique 
NMR spectroscopy involves the study of induced transitions between nuclear spin 
energy levels, whose degeneracy has been removed by the presence of a magnetic 
field. The magnetic moment (µ), which is characteristic of a specific nucleus, is 
defined by the equation: 
µ =   I 
where  is the gyromagnetic ratio,  is h/2	 (h = Planck’s constant) and I is the spin 
quantum number. It has no directional preference, however in the presence of a 
magnetic field (Bo, Tesla) its orientation becomes quantised and dependent on I 
through the equation: 
µz =   mI 
where mI is the magnetic quantum number, which has 2I + 1 integral values between 
+I and –I.  
To illustrate this, Figure 2.1 shows the two quantised levels of the nuclear magnetic 
moment for a nucleus with I = ½. These move in circular paths (precession) around 
the z-axis with the Larmor Frequency (
o), defined by 
o = Bo/2	. There is a 
preference for alignment of spins along the direction of Bo (+z) rather than against it 
(-z) and the population difference between these states is given by Boltzmann’s Law: 
n(+½)/n(-½) = exp (E/kT) where n is the population of the spin state and k is 
Boltzmann’s constant.  
In NMR experiments, the application of a second field, B1, at the Larmor frequency, 
causes these two states to interconvert with absorption of energy occurring on the +z 
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to –z transition and emission on the –z to +z transition. Due to the excess of +z spins, 
there is a net absorption of energy, known as resonance, which can be plotted versus 
frequency. Modern techniques use pulsed experiments, in which the nuclei are 
briefly irradiated periodically with an intense B1 field (length ~ < 10 µs). Between 
these pulses the spins relax to their original states leading to a decrease in 
magnetisation, known as the free induction decay (FID). This FID is Fourier 








Figure 2.1 The alignment of nuclear magnetic moments in the presence of the 
magnetic field, Bo, for a nucleus with I = ½. 
 
The observed resonance frequency (
o) is not only dependent on  and Bo, but also on 
the molecular environment of the nucleus as a result of the electron cloud 
surrounding it also possessing a magnetic moment. This phenomenon is known as 
(de)shielding and the variation in frequency as a result is termed the chemical shift. 
Furthermore, if another nucleus is nearby which also has a spin, the magnetic 
environment is also affected by this resulting in the appearance of a multiplet rather 
than a singlet. This spin-spin coupling is measured by the coupling constant, J (Hz), 
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and the nature of the multiplicities follows the 2nI + 1 rule, illustrating that it 
depends both on the nature and number of nearby spins. 
 
2.2.2 Water Supression 
A large majority of the NMR experiments performed in this thesis were on samples 
in aqueous solution (100% D2O or 95% H2O/5% D2O) so as to be of biological 
relevance. However, the use of such solvents results in a large HOD signal in the 
spectrum which requires suppression. This was achieved by either pre-saturation or 
Shaka[8] techniques. Pre-saturation involves saturating the water peak by irradiating 
with the frequency of the water signal in between pulse sequences. Shaka water 
suppression, or Double Pulse Field Gradient Spin Echo (DPFGSE), uses pulsed field 
gradient spin echos in which the refocusing pulse is the sequence                              
soft 	(x)-hard 	(-x)[8]. A disadvantage of the latter technique is that signals which 
resonate close to the water peak are also suppressed and therefore reduced in 
intensity. 
 
2.2.3 Two-Dimensional Techniques 
2.2.3.1 COrrelation and TOtal Correlation Spectroscopy (COSY and 
TOCSY) 
Correlation spectroscopy (COSY) is a two-dimensional homonuclear (1H-1H) 
technique which allows geminally (two-bond) or vicinally (three-bond) coupled 
protons to be identified by off-diagonal cross-peaks as a result of magnetisation 
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transfer between nuclei. Total correlation spectroscopy (TOCSY) is a similar 
technique to COSY, however coupling between all protons in the same spin system 
may be now observed through cross-peaks. This long-range correlation is obtained 
by maximizing the transfer of magnetisation by extending the length of the time 
delay between pulses, known as the mixing time. The latter technique is particularly 
useful in assigning spectra which correspond to a mixture of compounds. 
 
2.2.3.2 Nuclear Overhauser Effect Spectroscopy (NOESY) 
Nuclear Overhauser Effect spectroscopy (NOESY) is also a two-dimensional 
homonuclear (1H-1H) technique. It relies on the transfer of magnetisation from one 
proton to another through dipolar interactions on irradiation at the frequency of one 
of the nuclei. This phenomenon is known as the Nuclear Overhauser Effect. Similar 
to the TOCSY technique described previously, the mixing time is very important and 
should be as long as possible to allow for the maximum correlation between protons 
to be achieved. NOESY is a valuable technique for distinguishing between structures 
with clear stereochemical differences. 
 
2.2.3.3 Heteronuclear Spin-Quantum Coupling Spectroscopy (HSQC) 
Heteronuclear Spin-Quantum Coupling Spectroscopy (HSQC) facilitates couplings 
between protons and other nuclei (15N, 31P, 29Si, 13C for example) to be observed as 
cross-peaks on a two-dimensional spectrum. The experiments carried out in this 
thesis only involved proton-carbon (1H-13C) correlation and the magnetisation 
transfer between these nuclei allowed for the identification of protons bonded to 
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specific carbon atoms, therefore assisting with complete assignment of 1H and 13C 
resonances. Quaternary carbons are invisible to the technique since they possess no 
C-H bonds.  
 
2.2.4 Experimental 
All NMR spectra were recorded in 5 mm quartz NMR tubes at 298 K (unless 
otherwise stated) on either a Bruker DMX 500 (1H = 500.13 MHz) or AVA 600 (1H 
= 599.81 MHz) spectrometer using TXI [1H, 13C, 15N] or TBI [1H, 13C, 15N] probe-
heads equipped with z-field gradients. 1D and 2D spectra were recorded using 
standard pulse sequences modified by Mr Juraj Bella or Dr Dusan Uhrin, University 
of Edinburgh. 1H NMR chemical shifts were internally referenced to 1,4-dioxane 
(3.75 ppm) for aqueous solutions containing D2O, CHCl3 (7.27 ppm) for chloroform-
d1, (CHD2)(CD3)SO (2.52 ppm) for DMSO-d6 and MeOH (3.32 ppm) for methanol-
d4. All data processing was carried out using XWIN-NMR, Bruker UK Ltd (Version 
2.0 or 3.6). 
 
2.3 pH Measurements 
pH values were measured at ca. 298 K using a Coring 240 pH meter equipped with a 
Therom microcombination KCl (chloride) / KNO3 (chloride free) electrode calibrated 
with Aldrich standard buffer solutions at pH 4, 7 and 10. pH* values (pH meter 
readings without correction for effects of D on glass electrode) of NMR samples in 
D2O were measured directly in the NMR tube by the same method. 
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2.4 Calculation of pKa Values 
pKa values (the negative logarithm of the acid dissociation constant, Ka) were 
calculated through the use of NMR spectroscopy by the following method.  
The pH* values of solutions of the complexes in D2O were measured at ca. 298 K 
directly in the NMR tube before and after recording NMR data to obtain an average 
pH* value. The pH* values were varied from ca. 2 to ca. 11 by the addition of dilute 
NaOD or DClO4. 
1H NMR spectra were recorded and chemical shifts plotted against 
pH*. The resultant pH* titration curves were fitted to the Henderson-Hasselbalch 
equation using the program ORIGIN 7.5[9]. 
 
For the (de)protonation:                                 HA    H+   +    A- 
The Henderson-Hasselbalch Equation:          pH  =  pKa   +   log10([A
-]/[HA]) 
So that when half-dissociated:                        [HA] = [A-]   and    pH = pKa 
 
As a result of the fast exchange processes on the NMR timescale, the observed 
chemical shifts can be considered as weighted averages according to the populations 
of the protonated and deprotonated species. The modified Henderson-Hasselbalch 
equation is shown below, where δobs is the chemical shift at a given pH and δHA and 
δA- are the chemical shifts at low and high pH respectively
[10, 11]. 
obs  =     HA +  A- × 10 
(pKa* - pH*) 
            1 + 10 (pKa* - pH*) 
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The errors in the pKa* values obtained are estimated to be ± 0.05 pK units. The pKa* 
values were converted to pKa values by the use of the equation pKa = 0.929pKa* + 
0.42, suggested by Krezel and Bal[12], for comparison with related values in the 
literature. 
 
2.5 Electrospray Ionisation Mass Spectrometry 
Electrospray ionisation mass spectra (ESI-MS) were obtained on a Micromass 
Platform II Mass Spectrometer or a Micromass ZMD Mass Spectrometer 
(Micromass, Manchester UK) and solutions were infused directly at a rate of 5-30 
µL/min. The capillary voltage was 3.5 kV and the cone voltage was varied between 
10 and 40 V depending on sensitivity. The source temperature and mass range 
scanned were varied depending on the nature of the solution under investigation. 
Data acquisition was obtained on a MassLynx (Version 2.5) Windows NT PC data 
system. 
 
2.6 Ultraviolet-visible Spectroscopy 
Ultraviolet-visible (UV/Vis) spectroscopy was carried out on a Perkin-Elmer 
Lambda-16 UV/Vis spectrophotometer using 1 cm path-length quartz cuvettes and a 
PTP1 Peltier Temperature Controller. Unless otherwise stated, spectra were recorded 
at 298 K over a range of 800 – 200 nm at a scan rate of 420 nm min-1 and were 
processed using UV-Winlab software for Windows 95.  
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2.7 Electrochemistry 
Electrochemistry was carried out using platinum microworking and counter 
electrodes and an Ag/AgCl reference electrode. Analysis of experimental data was 
carried out using General Purpose Electrochemical System (GPES), version 4.8 
software, connected to an Autolab PGSTAT10 potentiostat. The inert electrolyte was 
tetrabutylammonium tetrafluoroborate (TBABF4) and solutions contained 0.1 M 
TBABF4 in N,N-dimethylformamide (DMF). All potentials were referenced to the 
ferrocene/ferrocinium couple (+0.55 V vs. standard calomel electrode, SCE) and 
coherency ensured by cleaning the working electrode with emery paper between 
measurements. Solutions were purged with dry nitrogen prior to study. 
 
2.8 X-ray Crystallography 
All diffraction data were collected and refined by Professor Simon Parsons and 
colleagues at The University of Edinburgh on a Bruker (Siemens) Smart Apex CCD 
Diffractometer using MoK radiation equipped with an Oxford Cryosystems low-
temperature device operating at 150 K. Structures were solved using direct 
(SHELXL-97[13]) methods and were refined against F2 using CRYSTALS[14]. H 
atoms were placed in calculated positions and non-H atoms were modelled with 
anisotropic displacement parameters. The modelling programs Mercury 1.4 and 
Diamond 3.0 were used for analysis of data and generation of graphics. 
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2.9 Circular Dichroism 
Circular dichroism (CD) data was obtained using a Jasco J-810 CD 
Spectropolarimeter with 1 mm path-length quartz cuvettes (300 – 400 L) and a 
Peltier temperature control unit. A constant flow of high purity nitrogen was supplied 
from a nitrogen generator. Spectra were recorded at 310 K from 500-200 nm unless 
otherwise stated and were processed using Jasco Spectra Manager software. 
 
2.10  High Performance Liquid Chromatography 
High Performance Liquid Chromatography (HPLC) was performed on a Gilson 
HPLC system with a NC100-5C18 reversed-phase column (250 × 4.6 mm, 100 Å, 5 
m, Hicrom). The mobile phases were A: water (purified using a Millipore Elix 5 
system) containing 0.1% trifluoroacetic acid (TFA) and B: acetonitrile (for HPLC 
application, Fischer Chemicals) containing 0.1% TFA with a flow rate of 1.0 mL 
min-1. The gradients used were dependent on the analysis mixture. Data were 
collected and analysed by Gilson applications Unipoint software (Version 3.0). 
 
2.11  Elemental Analysis 
Carbon, hydrogen and nitrogen (CHN) elemental analysis were carried out at either 
The University of Edinburgh in the School of Chemistry on an Exeter Analytical 
Elemental Analyser (CE440), or at The University of St. Andrews in the School of 
Chemistry on a Carlo Erba CHNS Analyser 
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2.12  Cytotoxicity Testing 
Cytotoxicity assays were performed on human ovarian A2780 and human lung A549 
cancer cell lines by Mr Daniel Cole and colleagues at Oncosense Ltd, MMI group, 
Cambridge, UK. As a measure of cytotoxicity, the concentration of the complex 
added to the cells which causes 50% inhibition of cell growth, termed the IC50 value, 
is determined. The cells were exposed to a number of different concentrations of the 
complexes typically ranging from 0.1 to 100 µM for 24 hours. Each concentration 
was tested in triplicate and two controls were used; a blank with no drug present and 
cisplatin, to act as a comparison. After 24 hours, the complexes were removed and 
the cells allowed to recover for 96 hours. The percentage cell survival was then 
determined using the Sulforrhodamine-B (SRB) assay[15] assuming 100% cell 
survival for the blank control. Percentage cell survival was then plotted versus 
complex concentration and the data fitted to the best-fit sigmoidal curve to obtain the 
IC50 value for each complex. A typical example of such a plot is shown in Figure 2.2. 
 
 
Chapter 2   Experimental Methods 
43 
 
Figure 2.2 A typical plot of percentage cell survival versus concentration obtained 
from cytotoxicity testing. The IC50 value for a complex can be determined by reading 
off the concentration which leads to 50% cell survival (red line). 
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3.1 Introduction 
Amino acids and peptides form an important group of biologically-active ligands and 
sometimes provide simple models for metal adducts with proteins. In addition they 
offer the possibility of probing the stereo-electronic requirements of specific receptor 
sites. Metal binding to amino acids in the active site is a key process for the function 
of a number of enzymes[1]. In an attempt to better understand the interactions 
observed, a number of metal-amino acid isolated systems have been studied in recent 
years. Previous work has focussed predominantly on metal binding via carboxylate, 
amino[2] and sulphur groups[3, 4] however, more recently, a number of full and half-
sandwich complexes have been prepared with 6-coordination to an aromatic side-
chain[5]. A range of organometallic derivatives of phenylalanine, tryptophan and 
tyrosine have been synthesised for metals such as ruthenium, iron, manganese and 
chromium through 6-coordination[2, 5, 6]. This Chapter discusses the synthesis, 
characterisation and properties of ruthenium complexes of two derivatives of indole 












L-tryptophan Indole-3-carbinol 1-methylindole-3-acetic acid  
Figure 3.1: The chemical structures of L-tryptophan and the two indole derivatives 
studied in this work. 
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Indole-3-carbinol is a naturally-occurring component of Brassica vegetables (e.g. 
cabbage, broccoli, cauliflower), formed during the enzymatic hydrolysis of indole 
glucosinolates on the cooking or chewing of such foodstuffs, and has shown potential 
as a chemopreventitive agent[7].  It is known to suppress cell proliferation and induce 
apoptosis in a number of cancers including prostate, ovarian and colon and has 
entered phase I and II clinical trials for the prevention of breast cancer[8]. A number 
of mechanisms for its activity have been proposed, however it is now widely 
accepted that indole-3-carbinol is a pro-drug which, on digestion, is converted by 
acid condensation and oligomerisation to a number of active metabolites[9]. The 
anticancer effects observed are thought to be due to the ability of these metabolites to 
interfere with the production of a number of key enzymes, including Akt protein 
kinase[8] and cytochrome P450[9]. 
Indole-3-acetic acid (auxin) is a plant growth hormone and is also found in mammals 
through consumption of vegetables and the metabolism of tryptophan[10]. Along with 
a number of its derivatives (including 1-methylindole-3-acetic acid), it induces 
apoptosis in mammalian cells (including tumour cells) through generation of radicals 
and reactive oxygen species as a result of oxidation by certain peroxidases[11-13]. 
Significantly, mammalian peroxidase does not exert this effect and therefore 
selective targeting of indole-3-acetic acid and an active enzyme (e.g. horseradish 
peroxidase) to a tumour is a promising strategy to significantly reduce side-effects 
and healthy tissue damage[14].  Its application in photodynamic therapy has also been 
identified; when used in conjunction with a photosensitising dye it has the potential 
to enhance the treatment of hypoxic tumours by generating reactive oxygen species 
without the need for high oxygen concentrations[15]. Various metal complexes of 
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indole-3-acetic acid and its derivatives have been synthesised, a number of which 
possess interesting biological activity[16, 17]. 
It is of interest to study organometallic complexes of these ligands as the latter’s 
bioactivity may be enhanced as a result of combination with the properties inherent 
to the metal. This has the potential to lead to drugs with wider spectra of activity and 
novel mechanisms of action. In addition, it is also possible that the metal could act as 
a carrier for the ligand, facilitating novel movement around the body and allowing 
delivery of the ligand to different targets. Confidence of the ability of the indole 
derivatives studied in this Chapter to form complexes with ruthenium came from the 
fact that the binding of L-tryptophan and its derivatives to ruthenium via 6-
coordination is described in the literature,[5, 18] and bis-arene complexes of indole and 




The starting material [(6-p-cymene)RuCl2]2 was prepared as described in Chapter 2. 
Indole-3-carbinol, 1-methyl-indole-3-acetic acid, silver trifluoromethanesulfonate 
(AgOTf) and silver hexafluorophosphate (AgPF6) ( 99%) were purchased from 
Sigma-Aldrich. Acetone was dried prior to use by refluxing with K2CO3.  
 








6-p-cymene)RuCl2]2 (0.03 g, 
0.05 mmol) was stirred in dry acetone (5 mL) with AgOTf (0.05 g, 0.20 mmol) for 
30 min at ambient temperature. The mixture was subjected to gravity filtration of the 
AgCl precipitate followed by centrifugation to give a clear red solution. Solvent 
removal under vacuum afforded a red, oily solid of the intermediate [(6-p-
cymene)Ru(acetone)3](OTf)2. This was re-dissolved in dry acetone (5 mL) and 
indole-3-carbinol (0.015 g, 0.10 mmol) added to the solution. The flask was wrapped 
in aluminium foil and the translucent red, solution was stirred for 18 h at 298 K. 
Addition of diethyl ether to the solution afforded a sticky red residue which could not 
be filtered. Therefore, the solvent was removed under vacuum and the product dried 
in vacuo. 
Anal. 1H NMR, 500MHz (d6-DMSO):  1.23 (dd, 6H, cymene), 2.11 (s, 3H, 
cymene), 2.80 (sp, 1H, cymene), 3.91 (d, 1H, indole CH2), 4.69 (d, 1H, indole CH2), 
5.94 (d, 1H, indole Ph), 6.07 (d, 1H, indole Ph), 6.11 (m, 1H, indole Ph), 6.40 (d, 2H, 
cymene), 6.51 (d, 2H, cymene), 6.93 (m, 1H, indole Ph), 7.19 (d, 1H, indole CH), 
7.99 (s, 1H, indole NH).  
A number of synthetic methods were explored for this complex, with the above route 
giving the best results, however the hygroscopic nature and fast rate of 
decomposition of this product did not allow for full characterisation. Details of the 
other synthetic methods attempted are be discussed in Section 3.3 and 3.4. 
 






-1-methylindole-3-acetic acid)](PF6)2 (2) [(
6-p-
cymene)RuCl2]2 (0.10 g, 0.16 mmol) was stirred in dry acetone (6 mL) with AgPF6  
(0.16 g, 0.64 mmol) for 30 min at ambient temperature. Filtration of the AgCl 
precipitate was carried out under Schlenk conditions yielding a transparent red 
solution. Excess solvent was removed under vacuum, affording a red oily residue of 
the intermediate [(6-p-cymene)Ru(acetone)3](PF6)2. A solution of 1-methylindole-3-
acetic acid (0.061 g, 0.32 mmol) in trifluoroacetic acid (TFA) (6 mL) was added to 
the Schlenk flask and the clear red solution stirred for 20 h at 333 K. After cooling, 
addition of diethyl ether to the resulting cloudy orange solution yielded a yellow 
powder which was filtered under gravity and dried in vacuo (Yield: 82 mg, 36.2%). 
Long yellow needle crystals of 2 suitable for X-ray diffraction were obtained by slow 
diffusion of gaseous diethyl ether into a methanol solution of the complex at 298 K. 
Anal. Found %C = 34.85; %H = 2.95; %N = 1.71. Calc. for C21H25NO2RuP2F12 (M = 
714.43): %C =35.29; %H =3.53; %N =1.96. ESI MS: Calc. for C21H24NO2Ru [M-H-
2PF6]
+ m/z 424.04, found 424.15. 1H NMR, 500MHz (D2O):  1.24 (dd, 6H, 
cymene), 1.93 (s, 3H, cymene), 2.71 (sp, 1H, cymene), 3.39 (s, 3H, indole N-CH3), 
3.45 (s, 2H, indole aliphatic CH2), 6.41 (d, 1H, cymene), 6.55 (t, 1H, Ph), 6.60 (m, 
3H, cymene + Ph), 6.74 (d, 1H, cymene), 7.64 (d, 1H, Ph), 7.70 (d, 1H, Ph), 8.25 (s, 
1H, indole).  
 
 




3.2.3.1 X-ray Crystallography 
Diffraction data for 2 were collected and refined as described in Chapter 2. The 
modelling programs Mercury 1.4 and Diamond 3.0 were used for analysis of data 
and generation of graphics. 
 
3.2.3.2 Calculation of pKa 
 Values 
For determination of the pKa values for 2, the pH* (pH values for D2O solutions) of 
the complex in D2O, containing 1% dioxane as an internal reference, was varied from 
ca. pH* 1.8 to ca. 8.5 by the addition of dilute NaOD and 1H NMR spectra recorded. 
The pKa values were obtained from the resultant data as described in Chapter 2. 
 
3.2.3.3 Stability Studies 
A solution of 2 in 95% H2O / 5% D2O at pH 7.04 (10 mM phosphate buffer) was 
prepared and 1H NMR spectra recorded at 310 K at time intervals of 3 h for 48 h 
followed by a final measurement after 72 h. The percentage of intact bis-arene 
complex present in solution at a particular time period was determined by peak-
integration relative to the internal reference (1% dioxane). The rate of decomposition 
of the complex was obtained by plotting these percentages versus time and fitting the 
data to the appropriate equation for first-order kinetics using the program ORIGIN 
7.5[21].  
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3.2.3.4 High Performance Liquid Chromatography – Electrospray 
Ionisation Mass Spectrometry (HPLC-ESI-MS) 
A Waters 2690 HPLC system using a NC100-5C18 reversed-phase column (250 × 
4.6 mm, 100 Å, 5 m, Hicrom) was interfaced with a Platform II mass spectrometer 
(Micromass, Manchester, U.K.) for the detection of positive ions. The mobile phase 
was A: water (purified using a Millipore Elix 5 system) containing 0.1% TFA and B: 
acetonitrile (for HPLC application, Fischer Chemicals) containing 0.1% TFA with a 
flow rate of 1.0 mL min-1. The gradient used was 90% A / 10% B for the first 5 
minutes then increase B to 90% over 20 minutes. The spray voltage and the cone 
voltage were 3.50 kV and 20 V respectively. The capillary temperature was 413 K 
with a 450 L h-1 flow of nitrogen drying gas. The quadrupole analyser operated at a 
background pressure of 2 × 10-5 Torr and scanned at a rate of 900 Da s-1. Data were 
collected and analysed on a Mass Lynx (version 3.5) Windows NT PC data system 
using the Max Ent Electrospray software algorithm and calibrated versus an NaI 
calibration file. 
 
3.2.3.5 Cytotoxicity Testing 
Cytotoxicity assays for 2 were performed against human ovarian A2780 and human 
lung A549 cancer cell lines by Mr Daniel Cole and colleagues at Oncosense Ltd, 
MMI group, Cambridge, UK as described in Chapter 2. 
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3.3 Results 
Due to the vast differences in properties between the two complexes investigated in 
this Chapter, experiments on them will be described separately. 
 
3.3.1 [(6-p-cymene)Ru(6-indole-3-carbinol)](OTf)2 (1) 
As pointed out in Section 3.2, in order to synthesise [(6-p-cymene)Ru(6-indole-3-
carbinol)](OTf)2 a number of approaches were attempted. A range of solvents were 
explored including acetone, dichloromethane and trifluoroacetic acid. Reaction 
temperatures and times were also varied from 298 K to 353 K and from 1 h up to 48 
h, respectively. In each case, the product was very hygroscopic and appeared to 
decompose on contact with air with a distinct colour change from dark orange to 
black, or in some cases deep purple, making full characterisation impossible. On 
analysis of these products by 1H NMR, the signals obtained were of very poor quality 
and all showed a broad signal in the aromatic region between 7 and 8 ppm. This was 
indicative of decomposition of the desired product into a number of species and also 
suggested polymer formation. The latter point was further implied by the high 
melting points of the products (573 – 598 K) and their low solubility. Attempts to 
purify the products of each reaction by a variety of methods resulted in no 
improvement to the 1H NMR spectra. 
The best results were obtained with the method outlined in Section 3.2.2 using dry 
acetone at 298 K for 18 h, however the product remained highly hygroscopic, 
preventing full analysis. The aromatic region of the 1H NMR spectrum is shown in 
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Figure 3.2 (A). 6-Coordination to ruthenium is confirmed by the characteristic 
upfield shift[6, 19] of the majority of signals corresponding to indole-3-carbinol 
compared to the free ligand, in addition to the slight downfield shift of the p-cymene 
protons relative to the half-sandwich starting material[5]. However, it appears that 
there is some unreacted mono-arene starting material present due to the presence of 
the doublet of doublets at 5.8 ppm which most likely corresponds to the p-cymene 
aromatic protons (x, Figure 3.2). The observation of the broad peak centred at 7 ppm 
could also suggest that some degree of oligomerisation has taken place. Attempts to 
separate components of this mixture by both column and high performance liquid 
chromatography were unsuccessful. Furthermore, re-recording of the spectrum after 
3 h resulted in dramatic changes as can be seen in Figure 3.2 (B). All structure to the 
signals has been lost with only a very broad band present in the aromatic region. This 
strongly suggests that [(6-p-cymene)Ru(6-indole-3-carbinol)](OTf)2 rapidly 
degrades in solution. 
The lack of stable complex formation combined with the inability to isolate and 
manipulate the desired product rendered [(6-p-cymene)Ru(6-indole-3-
carbinol)](OTf)2 (1) unsuitable for further study and therefore lead to the termination 
of work with this ligand. 
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Figure 3.2  Aromatic region of 1H NMR spectrum (d6-DMSO, 500 MHz) of 1 after 
(A) 0 h and (B) 3 h in solution. Signals corresponding to 1 and a mono-arene 
impurity (x) are labelled. 
 
3.3.2 [(6-p-cymene)Ru(6 - 1 – methylindole – 3 - acetic acid)](PF6)2 (2) 
 
3.3.2.1 Synthesis and Structure 
The ruthenium(II) bis-arene complex [(6-p-cymene)Ru(6 - 1 – methylindole – 3 - 
acetic acid)](PF6)2 (2) was successfully synthesised in a good yield from the 
corresponding chloro-bridged dimer [(6-p-cymene)RuCl2]2 and was characterised 
using 1H NMR spectroscopy, ESI-MS and elemental analysis. The data obtained are 
consistent with the sandwich structure shown in Figure 3.3 
 








Figure 3.3  Chemical structure of [(6-p-cymene)Ru(6-1-methylindole-3-acetic 
acid)](PF6)2 (2). 
 
3.3.2.2 X-ray Crystallography 
The X-ray crystal structure of [(6-p-cymene)Ru(6-1-methylindole-3-acetic 
acid)](PF6)2 (2) was obtained and is shown in Figure 3.4. It can be seen that the 
complex has crystallised as the methyl ester (2a), most likely due to the use of 
methanol in the crystallisation process. The structure shows the predicted bis-arene 
‘sandwich’ geometry with all six carbon atoms from both ligands involved in 	–
bonding to the ruthenium. Both bound phenyl rings appear to have regular 
geometries, with no significant angle distortions and have a staggered conformation 
with respect to each other. The ruthenium atom is not positioned centrally between 
the two arenes, but is closer to the p-cymene ligand with Ru-cymene(centroid) = 1.707 
Å and Ru-indole(centroid) = 1.757 Å. This suggests that the p-cymene possesses a 
greater interaction and better orbital overlap with the metal than 1-methylindole-3-
acetic acid. Crystallographic data are shown in Table 3.1 and selected bond lengths 
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and angles are listed in Table 3.2. The numbering scheme corresponds to that in 
Figure 3.4. 
Figure 3.4 X-ray crystal structure and atom numbering scheme for [(6-p-
cymene)Ru(6-1-methyl-3-indolemethyl acetate)](PF6)2  (2a). Thermal ellipsoids at 
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Table 3.1  Crystallographic data and solution refinements for [(6-p-cymene)Ru(6-
1-methyl-3-indolemethyl acetate)](PF6)2 (2a). 
 [(6-p-cymene)Ru(6-1-methyl-3-indolemethyl 
acetate)](PF6)2  (2a) 
Formula C22 H27 F12 N O2 P2 Ru 
[M] 728.46 
Colour Yellow 
Crystal system Triclinic 
Crystal size/ mm 0.41 x 0.16 x 0.10 
Space Group P-1 
a/ Å 9.5667(4) 
b/ Å 11.5209(4) 
c/ Å 13.2268(5) 
/ ° 68.935(2) 
/ ° 88.190(2) 
γ/ ° 86.977(2) 





Goodness of fit on F2 1.078 
Conventional R 0.0561 
Weighted R 0.1360 
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Table 3.2  Selected bond lengths (Å) and angles (°) for [(6-p-cymene)Ru(6-1-
methyl-3-indolemethyl acetate)](PF6)2 (2a). 
Bond / Angle Magnitude  
Ru (1) – C (2) 2.245 (4) 
Ru (1) – C (3) 2.206 (4) 
Ru (1) – C (4) 2.200 (3) 
Ru (1) – C (5) 2.227 (3) 
Ru (1) – C (6) 2.200 (4) 
Ru (1) – C (7) 2.211 (4) 
Ru (1) – C (11) 2.201 (4) 
Ru (1) – C (12) 2.239 (4) 
Ru (1) – C (13) 2.326 (3) 
Ru (1) – C (14) 2.351 (3) 
Ru (1) – C (15) 2.228 (4) 
Ru (1) – C (16) 2.187 (4) 
C (13) – C (14) 1.443 (5) 
C (13) – N (17) 1.368 (5) 
C (18)- C (19) 1.358 (6) 
C (7) – C (2) – C (3) 117.9 (3) 
C (2) – C (3) – C (4) 120.8 (3) 
C (3) – C (4) – C (5) 121.0 (3) 
C (6) – C (5) – C (4) 117.9 (3) 
C (5) – C (6) – C (7) 120.7 (3) 
C (2) – C (7) – C (6) 121.6 (3) 
C (12) – C (11) – C (16) 120.9 (3) 
C (13) – C (12) – C (11) 117.8 (4) 
C (12) – C (13) – C (14) 122.2 (3) 
C (15) – C (14) – C (13) 118.8 (3) 
C (14) – C (15) – C (16) 118.9 (3) 
C (11) – C (16) – C (15) 120.8 (4) 
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A particularly interesting feature is the length of the C (13) – N (17) bond, which, at 
1.368 Å, is almost as short as the C (18) – C (19) double bond at 1.358 Å. This can 
be ascribed to the electron-withdrawing power of the nitrogen atom in the pyrrole 
ring, which also results in significant lengthening of the C (13) – C (14) bond, 
making it over 0.02 Å longer than the other C-C bonds within the phenyl ring. An 
additional important point to note is that the indole ring is tilted by 7.172° along the 
C (12)-C (15) axis, which is illustrated in Figure 3.5.  
 
Figure 3.5 Crystal structure of cation in [(6-p-cymene)Ru(6-1-methyl-3-
indolemethyl acetate)](PF6)2 (2a), illustrating the tilting of the indole ligand. 
 
No intermolecular arene ring stacking was observed for this complex. The only 
significant interactions were the intermolecular hydrogen bonds of length 2.392 Å 
between O (21) and the H of C (11) on a second molecule (Figure 3.6). 
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Figure 3.6  Diagram illustrating the intermolecular hydrogen bonds in 2a. 
 
One of the most interesting features of the crystal structure is that the two molecules 
present in the unit cell are enantiomers (Figure 3.7) and therefore the complex exists 
as a 1:1 racemic mixture. These enantiomers are a result of facial chirality, arising 
due to the asymmetric ligand having two equally possible binding modes, with the 
methyl group pointing either towards or away from the viewer. No attempt was made 
to separate these, however it may be possible through diastereomeric resolution with 
a chiral anion for example. 
 













Figure 3.7   Chemical structures of the two possible orientations of the indole ring in 
2, giving rise to enantiomers with facial chirality. 
 
3.3.2.3 pH* dependence 
The 1H NMR chemical shifts of the indole -CH2 protons of [(
6-p-cymene)Ru(6 - 
1–methylindole–3-acetic acid)](PF6)2 (2) in D2O at 298 K were followed with 
changes in pH* over the range ca. 2 to ca. 8.5. These were then fitted to the 
Henderson-Hasselbalch equation (Figure 3.8) to obtain a pKa* value, which was 
converted to a pKa value for the carboxyl group of 3.52. This was repeated for the 
isolated ligand, which was found to have a considerably higher value of 6.25. The 
binding of 1-methylindole-3-acetic acid to ruthenium significantly increases the 
acidity of the carboxyl group by over 2.5 pK units. The results also indicate that the 
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Figure 3.8  Determination of pKa
* values. Dependence on pH* of the 1H NMR 
chemical shifts of the -CH2 protons of (A) 1-methylindole-3-acetic acid and (B) 
[(6-p-cymene)Ru(6-1-methylindole-3-acetic acid)](PF6)2
 (2). The curves represent 
the best fits to the Henderson-Hasselbalch equation, from which the pKa
* and pKa 
values were calculated. 
 
3.3.2.4 Stability Studies 
The 1H NMR spectra of 2 in 95% H2O / 5% D2O at pH 7.04 (10 mM phosphate 
buffer) were recorded at 310 K at time intervals of 3 h for 48 h followed by a final 
measurement after 72 h (Figure 3.9). After 6 h, new peaks were observed which 
appeared to correspond to free 1-methylindole-3-acetic acid (x) and a p-cymene 
mono-arene complex (2m). These continued to grow in over time with the 
simultaneous disappearance of the peaks corresponding to the intact bis-arene 
complex, and after 72 h complete conversion to the new species had taken place. A 
rate of 2.3 × 10-5 s-1 was obtained for the decomposition of 2 by plotting the 
percentage of the parent species versus time and fitting the data to the appropriate 
equation for first-order kinetics (Figure 3.10). 
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Figure 3.9 Decomposition of [(6-p-cymene)Ru(6-1-methylindole-3-acetic 
acid)](PF6)2
 
(2). 1H NMR spectra of 2 in 5% D2O/95% H2O at 310 K in 10 mM 
phosphate buffer (pH 7.04) after (A) 0 h, (B) 12 h and (C) 72 h, showing the 
decrease in intensity of the peaks corresponding to 2 and the increase in intensity of 
peaks for free 1-methylindole-3-acetic acid (x) and a mono-arene species (2m). 





















Figure 3.10  Decrease in intensity with time of 1H NMR signals corresponding to 
[(6-p-cymene)Ru(6-1-methylindole-3-acetic acid)](PF6)2
 
(2) in 5% D2O/95% H2O 
at 310 K in 10 mM phosphate buffer (pH 7.04). The curve represents the computer 
best-fit for a first-order reaction with a rate constant of 2.3 × 10-5 s-1. 
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Analysis of the 1H NMR reaction mixture at the 12 h time-point by electrospray mass 
spectrometry revealed three major peaks at m/z 212.6, m/z 390.0 and m/z 463.1, the 
latter two showing the isotopic pattern for a single ruthenium atom. Mass spectra 
simulations were carried out to aid identification of these species. M/z 212.6 
corresponds to free 1-methylindole-3-acetic acid plus a sodium ion picked up during 
the ionisation process [C11H11NO2Na
+, M=212.07]. The species responsible for the 
second peak at m/z 390.0 (2m) is most likely to be a mono-arene complex with a 
single p-cymene ligand. Given that the NMR solution contained only 2 and D2O, it is 
likely that 2m contains three bound solvent molecules to fill the coordination sphere 
of ruthenium. A postulated structure is [C10H15D2K2NaO3Ru
+, M=389.95]. The small 
peak at m/z 463.1 corresponds to 2, with the acid group having picked up a K+ ion 
[C21H24NO2RuK
+, M=463.06], illustrating the presence of some of the original 
complex. Similar analysis after 72 h revealed that only the m/z 212.6 and m/z 390.0 
species were present, consistent with the 1H NMR data that all intact bis-arene 
complex had been converted to free 1-methylindole-3-acetic acid and 2m.  
These results illustrate that [(6-p-cymene)Ru(6-1-methyl-3-indoleacetic 
acid)](PF6)2 is not stable in solution resulting in the loss of the 1-methylindole-3-
acetic acid ligand with time due to solvent molecule attack at the metal centre. In 
order to investigate this further, the behaviour of 2 in water and a more strongly 
coordinating solvent, dimethyl sulfoxide (DMSO), was studied by high performance 
liquid chromatography – electrospray ionisation mass spectrometry (HPLC-ESI-
MS). Solutions of 2 in the two solvents were prepared and immediately injected into 
the HPLC-ESI-MS system. The chromatogram obtained for the complex in H2O 
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showed only 1 peak (Figure 3.11) with a mass corresponding to the intact bis-arene 
complex 2. 
 
Figure 3.11  HPLC chromatogram of a solution of 2 in H2O. 
 
The HPLC chromatogram for a solution of 2 in DMSO shows two major peaks 
(Figure 3.12), neither of which elute at the same time as that observed for the H2O 
solution (Figure 3.11). In addition, the mass spectrum for the second eluted peak B 
(Figure 3.13) shows no ions corresponding to the intact parent complex. DMSO is a 
strongly coordinating solvent, therefore it is likely that the solvent induced 
degradation of 2 observed in D2O by 
1H NMR is accelerated and the mixture is 
therefore likely to be a number of decomposition products and solvent adducts. 
10.0 20.0 Time / min
 
Figure 3.12   HPLC chromatogram for solution of 2 in DMSO. 




Figure 3.13 Mass spectrum of second eluted HPLC peak (B, Figure 3.12) from a 
solution of 2 in DMSO.  
 
3.3.2.5 Cytotoxicity Studies 
Complex 2 was non-toxic towards both the human ovarian A2780 and human lung 




3.4.1 [(6-p-cymene)Ru(6-indole-3-carbinol)](OTf)2 (1) 
A detailed review of the chemistry and pharmacology of indole-3-carbinol by 
Broadbent and Broadbent states that the compound undergoes transformations in 
stomach acid to form various acid condensation and oligomerisation products, and it 
is these which are the active components against cancerous cells[7, 9]. However, this 
instability is not confined to in vivo, a number of in vitro studies have demonstrated 
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the formation of at least fifteen oligomers in acidic conditions (Figure 3.14)[22]. This 
process also occurs slowly at neutral pH with longer oligomer formation favoured as 
the pH is decreased[23]. The mechanism for these condensation reactions is thought to 
involve a stable, but highly reactive, benzylic-type carbocation which then attacks 
positions 2 or 3 of the indole ring of another molecule[24].Varying combinations of 































Figure 3.14 The chemical structures of indole-3-carbinol (I3C) and its major acid 
condensation and oligomerisation products[23]. 
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This clearly explains why initial synthetic attempts using the strong acid 
trifluoroacetic acid (pKa 0.3) failed. The use of this solvent is well reported in the 
literature for the synthesis of bis-arene complexes as it promotes 6-coordination of 
the ligand to the metal centre by the protonation of competing –donation sites such 
as carboxylate and amino groups[4, 6]. Improved success was obtained with more 
neutral solvents such as acetone, but the lack of pure product observed is likely to be 
due to the formation of both – and 	–bonded complexes in addition to slow 
oligomer formation.  
In addition to the reactions in acid, indole-3-carbinol is unstable with respect to light 
and the presence of oxidising agents also accelerates polymerisation[24]. Such contact 
with light was minimised by the wrapping of reaction vessels in aluminium foil. 
Although this appeared successful, with solutions turning orange during the reaction 
and evidence of a precipitate on cooling, reaction work-up under such conditions 
proved very challenging and in almost every case the reaction mixture turned very 
dark in colour and the precipitate became very sticky. Schlenk conditions were also 
employed to minimise contact with air, however on product isolation and analysis 
rapid absorption of moisture and degradation occurred, as indicated by the 1H NMR 
spectra obtained.  
The observed colour changes on contact with air are also interesting, particularly the 
development of a purple colour. This may indicate the formation of indigo. Although 
there is no literature report on such a transformation of indole-3-carbinol, indole is 
known to be oxidised to a number of indigoid pigments within the body[25]. Figure 
3.15 outlines the major pathway and intermediates thought to be generated during 
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this reaction. Although indigo is a major product it should be noted that a number of 
other pigments of similar structure are also formed. Due to the high reactivity of [(6-
p-cymene)Ru(6-indole-3-carbinol)](OTf)2 (1) observed, it is likely that in addition 
to the oligomerisation discussed, reactions leading to such pigments are also feasible, 
possibly through air oxidation, thus explaining the colour changes observed. 
















Indole IndigoIndoxyl  
Figure 3.15 Postulated major reaction pathway and intermediates for the in vivo 
generation of indigo from indole.  
 
Although what is known about the chemistry of indole-3-carbinol suggests that it is a 
very challenging compound to work with, it was hoped that if successful 6-
coordination to ruthenium was achieved, the electronics and properties of the ligand 
would be sufficiently altered for the product to remain stable. The extensive studies 
and variety of reaction conditions carried out clearly demonstrate that this is not the 
case, with evidence for the formation of a number of different species on contact 
with air or moisture even when bis-arene complex formation appears to have been 
successful. This instability of [(6-p-cymene)Ru(6-indole-3-carbinol)](OTf)2 (1) 
makes this system unsuitable for further study. Furthermore, it has little potential as 
an anticancer agent as, in addition to the fact that a pure, stable product could not be 
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obtained, its high reactivity would make determination of the exact nature of the 
species being investigated impossible. 
 
3.4.2 [(6-p-cymene)Ru(6 - 1 – methylindole – 3 - acetic acid)](PF6)2 (2) 
 
3.4.2.1 Synthesis and Structure 
[(6-p-Cymene)Ru(6-1-methylindole-3-acetic acid)](PF6)2 (2) was successfully 
synthesised using the method of Bennett and Matheson[27], employing trifluoroacetic 
acid as the reaction solvent. In addition to accurate mass spectrometry and elemental 
analysis data, 6 - coordination via the phenyl ring to generate a bis-arene complex 
was also confirmed by the characteristic upfield shift[19] of the signals for the 
aromatic protons of 1-methylindole-3-acetic acid on metal binding combined with 
the downfield shift of the aromatic protons of p-cymene relative to the half-sandwich 
starting material[6]. 
 
3.4.2.2 X-ray Crystallography 
The crystal structure of the methyl ester [(6-p-cymene)Ru(6-1-methyl-3-
indolemethyl acetate)](PF6)2 (2a) confirms the expected bis-arene structure with two 
essentially parallel 6-arene ligands. The angle between the ruthenium and the centre 
of each ring is 179.0° which is comparable to that observed for similar complexes [19, 
20]. 
Chapter 3   Ruthenium Complexes of Indole Derivatives 
72 
The observed tilting of the indole ring by 7.172° along the C (12)-C (15) axis is 
interesting and indicates some loss of η6-coordination to the ruthenium. This is 
further corroborated by the fact that the Ru – C(13) and Ru – C(14) are 2.326(3) Å 
and 2.351(3) Å respectively, significantly longer than the Ru – C distances for the 
other coordinated indole carbon atoms (2.187 – 2.239 Å). The observed 
intermolecular hydrogen bonds in the crystal structure of 2a could be a contributory 
factor to this. However, the main origin is thought to be the fact that the two ring 
junction carbons (C(13) and C(14)) are not able to 	-bond as effectively with the 
metal as the other ring carbons as their 	–electrons are involved in bonding to three 
other carbons instead of two[28]. This phenomenon, also known as ‘ring slippage’, has 
been shown for other complexes containing indole rings, for example, [(6-p-
cymene)Ru(6-5-OTrpOH)](OTf)2 shows a tilting angle of 12.4º
[5], in addition to a 
range of other metal-arene systems[28]. 
A consequence of this ring-tilting may be the creation of a space large enough for 
solvent molecules to attack the ruthenium centre and form new species and it is 
therefore a possible explanation for the observed arene loss for this complex in 
solution. Arene displacement reactions are thought to occur by attack of the external 
(solvent) ligand after 6-4 dissociation of the arene[28]. It therefore follows that for 
complexes with coordinated arene rings which are tilted, such as 2, arene lability is 
enhanced due to the greater accessibility of the metal centre[29]. 
Indole and its derivatives are generally thought of as electron-rich heterocycles due 
to the involvement of the nitrogen lone pair in the aromatic 	–system. The electron 
withdrawing nature of the 5-membered pyrrole ring is exemplified in the crystal 
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structure by the shortening of the C (13) – N (17) bond, implying that the benzene 
ring component of the indole ligand is electron-poor compared to the p-cymene 
ligand which contains only electron-donating methyl substituents. This, combined 
with the observed ‘ring slippage’, is likely to be the reason why the p-cymene ligand 
is closer to the metal by over 0.05 Å compared to 1-methylindole-3-acetic acid. The 
Ru-cymene(centroid) distance of 1.707 Å is very similar to that observed for [(
6-p-
cymene)Ru(6-1-methylindole)](OTf)2 of 1.706 Å
[19] and both are significantly 
longer than the average distance in other (cymene)Ru(arene) derivatives of 1.678 
Å[30]. Similarly, the Ru-indolemethyl acetate(centroid) distance of 1.757 Å for 2a is 
comparable to that of the indole complex (1.761 Å)[19]. A parallel trend was observed 
for [(6-p-cymene)Ru(6-1–methylindoline)](BPh4)2 where Ru-cymene(centroid) = 
1.730 Å and Ru-indole(centroid) = 1.773 Å
[20].  
Interestingly, the facial chirality observed for 2a is also well documented for other 
closely related systems. Most show enantiomer ratios of 1:1 in the crystal structures[4, 
20] indicating no preference for one isomer over the other, however in one case of 
facial chirality preferential crystallisation of one diastereomer was reported[5]. 
 
3.4.2.3 pH* Dependence 
The pKa value for the carboxyl group of 1-methylindole-3-acetic acid is significantly 
lowered from 6.25 to 3.52 on metal binding. This trend in increased acidity is 
consistent with many other similar bis-arene complexes in the literature[4, 5, 20]. 
However, this change will have no effect on the nature of the species at physiological 
pH.  
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The NH group on an indole ring is weakly acidic with a pKa value of 16.97, with 
indole-3-acetic acid having a very similar value of 16.90[31], although much enhanced 
acidity is observed over ammonia (pKa ~22)
[7]. The bascitiy of the nitrogen atom is 
accordingly reduced compared to ammonia (pKb = -3.6, cf. 4.75). This is a result of 
indole being a 	–rich heterocycle with delocalisation of the nitrogen lone pair into 
the 	–system. This leads to enhanced 	–electron density on the carbon atoms and 
reduced density on the nitrogen[7]. Since the nitrogen is methylated in 2, this group 
would be expected to behave as a base. However, even with the electron-donating 
properties of the methyl group, the enhanced acidity resulting from metal 
coordination would most likely result in a pKb value well below -3.6 and hence its 
measurement was not possible under the conditions studied. 
 
3.4.2.4 Stability Studies 
The observed loss of the 1-methylindole-3-acetic acid arene ligand from 2 in solution 
is unusual. In the literature, there are several examples of photochemical 
displacement of an 6-arene from ruthenium for both mono- and bis-arene systems, 
[32, 33] but such thermal displacement under mild conditions is much more rare [34, 35]. 
The observed arene loss can be rationalised not only by considering the loss of 6-
coordination, implied by the crystal structure, but also by the nature of the bonding 
of the arene to Ru(II), which is strengthened by increasing the amount of 	–electron 
density on the arene ligand which can be donated to the metal centre[29]. Indole and 
its derivatives have a tightly bound and stable 	-electron system and disruption of 
this is unfavourable. Therefore, in [(6-p-cymene)Ru(6-1-methylindole-3-acetic 
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acid)](PF6)2 (2), the indole-3-acetic acid ligand is less tightly bound due to 
competition between the ruthenium and the 	–system of the heterocycle for the 	–
electron density.  
 
3.4.2.5 Cytotoxicity 
The non-toxic nature of 2 towards both the human ovarian A2780 and human lung 
A549 cancer cell lines at concentrations up to 100 µM is unlikely to provide a 
general guide to the toxicity of this complex. The cytotoxicity studies involve 
dissolution of the complexes in a DMSO/water mixture prior to addition to the cells. 
The results obtained from the stability studies on this complex clearly show that 2 
would break down in such a solvent mixture and therefore it is most likely that it is 




Two novel bis-arene ruthenium complexes of indole derivatives, [(6-p-
cymene)Ru(6-indole-3-carbinol)](OTf)2 (1) and [(
6-p-cymene)Ru(6-1-methyl-
indole-3-acetic acid)](PF6)2 (2) were synthesised and studied in this work. It was 
hoped that the known biological properties of the ligands would lead to novel metal 
complexes with anticancer properties. 
[(6-p-Cymene)Ru(6-indole-3-carbinol)](OTf)2 (1) was found to be highly reactive, 
with rapid decomposition of the complex into a wide range of oligomeric products 
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occurring on contact with air and in solution. A variety of synthetic conditions were 
investigated, none of which resulted in stable complex formation, and it was not 
possible to isolate the desired product. 
[(6-p-Cymene)Ru(6-1-methyl-indole-3-acetic acid)](PF6)2 (2) formed an air-stable 
bis-arene complex with ruthenium, however loss of the indole ligand occurs in 
solution. The rate of this arene loss is 2.3 × 10-5 s-1 in aqueous solution and increases 
dramatically in more strongly coordinating solvents such as DMSO. Coordination of 
the indole derivative to the metal centre resulted in a dramatic increase in the acidity 
of the ligand, as shown by the decrease in pKa of the carboxyl group from 6.25 to 
3.52. The X-ray crystal structure of 2 was obtained as the methyl ester (2a) and it 
was found that the two molecules in the unit cell were enantiomers as a result of 
facial chirality. The indole ring is tilted by 7.172° in the solid state, implying some 
degree of loss of 6-coordination. This, if also present in solution, may be a 
contributing factor to the observed dissociation of the ligand. 
The racemic mixture of 2 was found to be non-toxic against both the A2780 breast 
cancer and A549 lung cancer cell lines. However, due to the time dependent 
breakdown of the compound, it is likely that a mixture of products were being tested 
and therefore no direct conclusions about the activity of the intact complex can be 
made.  
This work demonstrates that although amino acids and their derivatives readily form 
stable bis-arene complexes with ruthenium[5, 6, 19], very minor changes to their 
electronic structure (replacement of H by Me for example) can drastically affect their 
properties and reactivity, and careful consideration of the whole system is necessary. 
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Unfortunately, due to the highly reactive nature of both complexes studied here, it is 
unlikely that either would be suitable for such an application. However, if the rate of 
loss of 1-methylindole-3-acetic acid from the metal centre could be controlled, it is 
possible to envisage the metal acting as a carrier, with delivery of the ligand to 
specific sites within the body, imparting novel properties to the complex. 
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4.1 Introduction 
In Chapter 3, the potential of binding two amino acid derivatives to ruthenium in 
order to generate metal complexes with applications as anticancer agents was 
discussed. Here, the feasibility of extending work on such a class of ligands is 
investigated by exploring the synthesis and properties of ruthenium and osmium 
complexes of a dipeptide, -L-aspartyl-L-phenylalanine methyl ester, aspartame. 
There are far fewer examples of bis-arene metal complexes containing peptides 
compared to single amino acids, however a limited number of systems have been 
investigated[1, 2]. Recently, this work has been extended to small proteins where 
selective binding of a ruthenium organometallic fragment to a phenylalanine residue 
of secretin via 6-coordination in aqueous media was achieved[3]. Synthesis of 	–
bound peptides may be achieved by direct binding to the metal or through peptide 
synthesis on the side-chain of a metal-bound amino acid[4]. This leads to interesting 
synthetic applications if the organometallic fragment facilitates novel couplings and 
may then be removed at the end of the reaction[5]. 
Aspartame (-L-aspartyl-L-phenylalanine methyl ester,  Figure 4.1) is a low-calorie 
sweetener[6]. It is a white, odourless powder with a sweetness potency of up to 200 
times that of sucrose[7]. On consumption it is rapidly converted into a number of 
decomposition products and, eventually, into its three constituents: aspartic acid, 
phenylalanine and methanol[8]. Aspartame is thought to interact with the sweet taste 
receptor via three important functionalities: the carboxylate and amino groups 
through electrostatics and hydrogen bonding, and the aromatic ring via hydrophobic 
interactions[9].  
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In addition to these well studied biological reactions of aspartame, it has also been 
shown to interact with DNA in vitro through electrostatic binding between the amino 
group and the phosphate backbone of DNA in addition to a partial intercalation of 
the aromatic ring[10]. Although there have been a number of reports associating 
aspartame intake with an increased risk of cancer, a recent review of a variety of 
clinical studies has found no link between the two and that at current levels of 
consumption, the sweetener is harmless to humans[11]. There is no known anticancer 









O NH2  
Figure 4.1   Chemical structure of aspartame (-L-aspartyl-L-phenylalanine methyl 
ester) 
 
Reports on metal coordination complexes of aspartame are at present limited to 
metals such as copper, nickel and zinc, in which binding occurs through the 
carboxylate and amino groups[12, 13]. To date, there have been no investigations into 
whether or not these metal complexes retain any of the activity inherent to 
aspartame. This chapter describes the synthesis and characterisation of complexes of 
ruthenium(II) and osmium(II) containing aspartame bound through 6-coordination 
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and investigations of reactions of potential importance for their biological activity. In 




The preparation of the starting materials [(6-p-cymene)RuCl2]2 and [(
6-p-
cymene)OsCl2]2 is reported in Chapter 2. Aspartame was purchased from Supelco 
Analytical, ascorbic acid from Alfa Aesar and silver trifluoromethanesulfonate 
(AgOTf) ( 99%) from Sigma-Aldrich. Acetone was dried by reflux over K2CO3 








6-p-cymene)RuCl2]2 (0.13 g, 0.2 
mmol) was stirred in dry acetone (7 mL) with AgOTf (0.22 g, 0.8 mmol) for 30 min 
at ambient temperature. Removal of the AgCl precipitate by filtration was carried out 
under Schlenk conditions yielding a clear red solution. Excess solvent was removed 
under vacuum, affording a red oily residue of the intermediate [(6-p-
cymene)Ru(acetone)3](OTf)2. A solution of aspartame (0.12 g, 0.4 mmol) in 
trifluoroacetic acid (6 mL) was added to the Schlenk flask and the clear red mixture 
stirred for 18 h at 323 K. After cooling, addition of diethyl ether, to the resulting 
cloudy orange solution, resulted in the formation of a yellow crystalline precipitate 
which was filtered, washed with ether and dried in vacuo. (Yield: 185 mg, 55.9%).  
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Anal. Found %C = 38.29; %H = 4.10; %N = 3.55. Calc. for C26H32N2O11RuS2F6 (M 
= 827.73): %C = 37.73; %H = 3.87; %N = 3.39. ESI MS: Calc. for 
C26H32N2O11RuS2F6 [M+H]
+ m/z 829.04, found 828.73. 1H NMR, 600MHz (D2O):  
1.32 (d, 6H, cymene), 2.49 (s, 3H, cymene), 2.95 (sp, 1H, cymene), 3.07 (m, 3H, 
Asp), 3.35 (dd, 1H, Asp), 3.78 (s, 3H, Asp), 4.36 (dd, 1H, Asp), 4.88 (dd, 1H, Asp) 







6-p-cymene)OsCl2]2 (0.051 g, 0.06 
mmol) was stirred in dry acetone (3 mL) with AgOTf  (0.069 g, 0.24 mmol) for 30 
min at ambient temperature. Filtration of the AgCl precipitate yielded a clear orange 
solution. Excess solvent was removed in vacuum, affording an orange oily residue of 
the intermediate [(6-p-cymene)Os(acetone)3](OTf)2. Aspartame (0.038 g, 0.12 
mmol) in trifluoroacetic acid (5 mL) was then added to the [(6-p-
cymene)Os(acetone)3](OTf)2 and the clear orange mixture stirred for 20 h at 333 K. 
After cooling, diethyl ether was added to the resulting yellow solution, to form a 
yellow/white powder which was filtered and washed with diethyl ether. (Yield: 43 
mg, 39.4%)  
Anal. Found %C = 34.57; %H = 3.66; %N = 3.59. Calc. for C26H32N2O11OsS2F6 (M 
= 916.6): %C = 34.07; %H = 3.49; %N = 3.06. ESI MS: Calc. for OsC24H31N2O5
+ [M 
–H - 2CF3SO3]
 + m/z 619.19, found 619.20. 1H NMR, 600 MHz (D2O):  1.34 (d, 6H, 
cymene), 2.29 (s, 3H, cymene), 2.74 (sp, 1H, cymene), 3.00 (m, 4H, Asp), 3.72 (s, 
3H, Asp), 4.30 (dd, 1H, Asp), 4.73 (dd, 1H, Asp), 7.30 (m, 9H, cymene + Ph). 
 




4.2.3.1 pH measurements  
pH and pH* values were measured at ca. 298 K directly in the NMR tube as 
described in Chapter 2.  
 
4.2.3.2 Calculation of pKa Values  
For determination of pKa* values (pKa values determined for D2O solutions), the pH* 
values of the solutions of aspartame and complexes 3 and 4 in 5% MeOD-d4/95% 
D2O were varied from ca. 2 to ca. 11 by the addition of dilute NaOD and DClO4. 
1H 
NMR spectra were recorded and chemical shifts plotted against pH*. The pH* 
titration curves were fitted, using the program ORIGIN 7.5[14], to the modified 
Henderson-Hasselbalch equation appropriate for two pKa
* values[15] where δobs is the 
chemical shift at a given pH and δHH’A, H’A- and δA2- are the chemical shifts at low, 
intermediate and high pH respectively. 
 
 
For the (de)protonation:      HH’A    H+  +   H’A-     H’+   +   A2- 
 
obs  =     HH’A + (H’A
- - HH’A)  × 10 
(pH* - pKa1*)    + (A2- - H’A-)   × 10 
(pH* - pKa2*) 
            1 + 10 (pH* - pKa1*)                            1 + 10 (pH* - pKa2*)     
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The pKa* values were converted to pKa values by the use of the equation pKa = 
0.929pKa* + 0.42, as suggested by Krezel and Bal
[16], for comparison with related 
values in the literature. 
 
4.2.3.3 Stability Studies 
Solutions of aspartame, 3 and 4 in 5% MeOD-d4/5% D2O/90% H2O at pH 7.4 (10 
mM phosphate buffer) containing 1% dioxane as an internal reference were prepared 
and 1H NMR spectra recorded at 310 K at time intervals of 0.5 h for 24 h. The 
percentage conversion of aspartame to 3,6-dioxo-5-phenylmethylpiperazine acetic 
acid (diketopiperazine, DKP) at a particular time period was determined by peak-
integration relative to the internal reference, assuming integration at a time of 0 h 
corresponded to 0%. The rate of the reaction observed was obtained by plotting these 
percentages versus time and fitting the data to the appropriate equation for first-order 
kinetics using the program ORIGIN 7.5[14].  
 
4.2.3.4 Electrochemistry 
Electrochemistry was carried out using the standard method described in Chapter 2. 
Cyclic voltammetry was carried out on solutions of aspartame in 0.1 M 
tetrabutylammonium tetrafluoroborate (TBABF4) in N,N-dimethylformamide (DMF) 
with a sweep width of between +2 and -2 V and with sweep rates of between 0.1 and 
1 Vs-1. Differential pulse polarography was carried out on analogous solutions of 
complexes 3 and 4 over the same potential range due to its enhanced sensitivity[17] 
which allowed each redox process to be observed at lower concentrations.  
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4.2.3.5 Reactions with Ascorbate 
Solutions of aspartame, 3 and 4 at 100 µM in D2O at pH 7.04 (10 mM phosphate 
buffer) containing 1% dioxane as an internal reference were prepared and the 1H 
NMR spectra recorded at 310 K. Aliquots of a solution of ascorbic acid in D2O were 
added at a number of different excess concentrations (5-50 equivalents) and the 1H 
NMR spectra re-recorded at time intervals of 0.5 h for 24 h. The rate of the reaction 
observed for 3 was obtained by plotting the decrease in intensity of a number of 
peaks (relative to internal reference) versus time and fitting the data to the 
appropriate equation for pseudo-first order kinetics using the program ORIGIN 
7.5[14].  
 
4.2.3.6 Cytotoxicity Testing 
Cytotoxicity assays for 3 were performed against human ovarian A2780 and human 
lung A549 cancer cell lines by Mr Daniel Cole and colleagues at Oncosense Ltd, 
MMI group, Cambridge, UK as described in Chapter 2. 
 
4.2.3.7 Heterologous Expression to Monitor Interaction with Sweet 
Taste Receptor 
The ability of 3 and 4 to interact with the human sweet taste receptor was monitored 
using the following assay by Dr Marcel Winnig and colleagues at The German 
Institute of Human Nutrition, Nuthetal, Germany. The complementary DNAs for 
hTAS1R2 and hTAS1R3 were transiently transfected into HEK293T cells stably 
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expressing the chimeric G-protein subunit G16gust44[18] using Lipofectamine 2000 
(Invitrogen) [19]. 4 h post transfection, Dulbecco’s modified Eagle’s medium 
(DMEM) was replaced by low-glucose DMEM supplemented with GlutaMAX and 
10% dialyzed foetal bovine serum (FBS, Invitrogen). After an additional 24 h, cells 
were loaded for 1 h with the calcium-sensitive dye Fluo4-AM (2 g/mL in DMEM, 
Molecular Probes). Cells were washed 3 times with solution C1 (130 mM NaCl, 5 
mM KCl, 10 mM HEPES, 2 mM CaCl2, and 5 mM Glucose, pH 7.4). The aspartame 
complexes were dissolved in C1 solution. Calcium mobilisation upon stimulation 
was monitored by an automated fluorometric imaging plate reader (FLIPR, 
Molecular Devices) and the calcium signals were corrected for the response of mock 
transfected cells. 
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4.3 Results 
4.3.1 Synthesis and Structure 
Both the ruthenium(II) and osmium(II) bis-arene complexes containing aspartame 
were synthesised in good yields from the corresponding chlorido-bridged dimers, 
[(6-p-cymene)MCl2]2 (M = Ru/Os), and were characterised using 
1H NMR 
spectroscopy, ESI-MS and elemental analysis. 6 - coordination via the phenyl ring 
was also confirmed by the characteristic upfield shift of the signals for the aromatic 
protons of aspartame on metal binding. These data are consistent with the sandwich 




Figure 4.2  The chemical structure of the metal aspartame sandwich complexes 3 (M 
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4.3.2 pH* dependence and pKa values 
The 1H NMR chemical shifts of the -CH and -CH2 protons of the aspartic acid 
residue of aspartame at 298 K in 5% MeOD-d4/95% D2O were followed with 
changes in pH* over the range 2-11. This procedure was repeated for the ruthenium 
and osmium complexes and the data for those peaks with the most significant shifts 
were fitted to the Henderson-Hasselbalch equation (Figure 4.3) to obtain pKa* 
values. These were converted to pKa values of 3.45, 3.10 and 2.94 for the carboxyl 
groups, and 7.81, 7.32, and 7.24 for the amino groups of aspartame, 3, and 4, 
respectively (Table 4.1). Importantly, the binding of aspartame to Ru or Os via the 
phenyl group lowers the pKa values of both the carboxyl and amino groups 
significantly (by ca. 0.5 units).  
 
 
Table 4.1  pKa values for aspartame, ruthenium complex 3 and osmium complex 4 




   
Aspartame 3.45(1) 7.81(4) 
3 3.10(1) 7.32(3) 
4 2.94(1) 7.24(3) 
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Figure 4.3  Determination of pKa
* values. Dependence on pH* of the 1H NMR 
chemical shifts of the -proton of (A) aspartame, (B) [(6-p-cymene)Ru(6-
aspartame)]2+ (3), and –protons of (C)  [(6-p-cymene)Os(6-aspartame)]2+ (4). The 
curves represent the best fits to the Henderson-Hasselbalch equation for two pKa 
values and the pKa
* values to which they correspond were converted to the pKa 
values shown in Table 4.1.  
 
4.3.3 Stability Studies 
Aspartame is known to degrade in aqueous solution[8]. Under physiologically-
relevant conditions (310 K, pH 7.4), the primary step in this degradation is 
considered to be the formation of 3,6-dioxo-5-phenylmethylpiperazine acetic acid 
(diketopiperazine, DKP) via the intramolecular cyclisation reaction outlined in 
Scheme 4.1[20].  
 




















































Scheme 4.1 Mechanism for the conversion of aspartame to DKP through an 
intramolecular cyclisation reaction 
 
The behaviour of aspartame and the Ru and Os complexes under such conditions was 
monitored in 5% MeOD-d4/5% D2O/90% H2O, 10 mM phosphate buffer (pH 7.4) 
solutions using 1H NMR spectroscopy over a 24 h period. All spectra showed growth 
of a peak for free methanol and disappearance of the signal for the OMe group of 
bound aspartame over this time (aspartame spectra shown in Figure 4.4), in 
accordance with the proposed mechanism. Analysis of 1H NMR peak integrals 
allowed the percentage conversion of aspartame to DKP to be plotted versus time 
(Figure 4.5). The resultant data were fitted to first-order kinetics from which rates 
and half-lives for the degradation were obtained. A dramatic increase in rate constant 
from 0.12 h-1 for aspartame to 0.36 h-1 for 3 and 0.43 h-1 for 4 was observed. It is 
interesting that osmium has a more pronounced effect on this pathway (by 1.2 fold). 
 
 














3.4 3.03.2 2.8 ppm







Figure 4.4 Conversion of aspartame into DKP. 1H NMR spectra of aspartame in 5% 
MeOD-d4/5% D2O/90% H2O at 310 K in 10 mM phosphate buffer (pH 7.4) after (A) 
0 h, (B) 4 h, (C) 8 h, (D) 12 h and (E) 16 h, showing the decrease in intensity of the 
peak for bound OMe at 3.51 ppm (c) and the increase in intensity of the peak for free 
MeOH (x). A small downfield shift of ca. 0.02 ppm for peaks between 2.7 and 2.9 
ppm is also observed. Peak labels correspond to the structure shown. 
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Figure 4.5   Time dependence of the formation of DKP for (A) aspartame, (B) [(6-
p-cymene)Ru(6-aspartame)]2+ (3) and (C) [(6-p-cymene)Os(6-aspartame)]2+ (4) in 
5% MeOD-d4/5% D2O/90% H2O at 310 K in 10 mM phosphate buffer (pH 7.4), as 
determined by 1H NMR spectroscopy. The curves represent the computer best-fits 
for first-order reactions with rate constants of 0.12 h-1 for aspartame (half life = 6.01 
± 0.56 h), 0.36 h-1 for 3 (half life = 1.95 ± 0.08 h), and 0.43 h-1 for 4 (half life = 1.60 
± 0.05 h).  
 
The major ESI-MS peaks observed from the NMR samples after 24 h at low cone 
voltage (10 V) were m/z 261.78, 646.53 and 735.54 for aspartame, 3 and 4, 
respectively, consistent with the formation of DKP+, [(6-p-cymene)Ru(6-
DKP)](OTf)+ and [(6-p-cymene)Os(6-DKP)](OTf)+ (calcd m/z 262.10, 647.06, 
747.12). The data for 3 and 4 are shown in Figure 4.6. The proposed pathway was 
thus confirmed, and the ESI-MS data eliminated the possibility that the observed 
NMR spectral changes were caused by hydrolysis of the ether bond.  These results 
also illustrate the stability of the metal-arene bonds in these complexes since they 
remained intact throughout. 
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Figure 4.6   Characterisation of metal – DKP adducts. ESI mass spectra of solutions 
of (A) [(6-p-cymene)Ru(6-aspartame)]2+ (3) and (B) [(6-p-cymene)Os(6-
aspartame)]2+ (4) in 5% MeOD-d4/5% D2O/90% H2O after 24 h. Peaks at m/z 646.53 
and 735.54 correspond to {[(6-p-cymene)Ru(6-DKP)](OTf)}+ and {[(6-p-
cymene)Os(6-DKP)](OTf)}+ (calcd m/z 647.06, 737.12), respectively. 
 
4.3.4 Electrochemical Behaviour 
The redox properties of aspartame, 3 and 4 were investigated in the presence of 0.1 
M tetrabutylammonium tetrafluoroborate (TBABF4) as the supporting electrolyte in 
N,N-dimethylformamide (DMF).  
The cyclic voltammogram of aspartame shows a quasi-reversible reduction peak at -
1.133 V (E1/2 = 0.946 V) at a scan rate of 0.1 Vs
-1 (Figure 4.7). Due to the small 
amounts of material available, the more sensitive technique of differential pulse 
polaragraphy was used to investigate the ruthenium and osmium complexes. The 
introduction of a metal centre caused an increase in complexity of the redox 
behaviour, a shift in the reduction to less negative potentials, and a change in the 
reversibility of the process. Complex 3 exhibited a two-step reductive process at -
0.377 V and -0.664 V, the latter showing a reverse wave at -0.643 V (Figure 4.8A). 
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Contrastingly, 4 was reduced in a single step at -0.619 V with a reverse wave at          
-0.177 V (Figure 4.8B). The large separation in the peaks for the osmium complex 
suggests that a chemical reaction follows reduction, most likely due to movement of 
the electrons within the system. Unfortunately, it was not possible to identify the 
products of these transformations.   
 
Figure 4.7  Cyclic voltammogram of aspartame in 0.1 M TBABF4/DMF at a scan 
rate of 0.1 Vs-1 corresponding to a quasi-reversible reduction with E1/2 = 0.946 V. 
 
 
Figure 4.8 Forward (dashed line) and reverse (solid line) square-wave 
voltammograms of (A) [(6-p-cymene)Ru(6-aspartame)](OTf)2
 (3) and (B) [(6-p-
cymene)Os(6-aspartame)](OTf)2
 (4) in 0.1 M TBABF4/DMF. 
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The electrochemical reduction potentials indicate that only the ruthenium complex 
possesses redox activity within a biologically-relevant range of potentials (0 to – 0.5 
V)[21]. 1H NMR studies of reactions of the complexes with an excess of the biological 
reductant ascorbic acid (pKa 4.2, ascorbate anion at physiological pH) were studied at 
310 K in D2O solutions containing 10 mM phosphate buffer (pH 7.04). Over a 24 h 
period, the only change observed in the 1H NMR signals of aspartame and the 
osmium complex was the loss of bound OMe and growth of free MeOH peaks due to 
DKP formation. Contrastingly, many of the peaks corresponding to the ruthenium 
complex disappeared or changed appearance with time (Figure 4.9).  
Kinetic data were derived by following changes in peak intensity, relative to an 
internal reference, for a number of different excess ascorbate concentrations (5-50 
equivalents). The rate was found to be independent of the latter and the pseudo-first-
order rate constant was determined to be ca. 6.9 x 10-5 s-1 (half-life 2.8 h; Figure 
4.10). Unfortunately, full characterisation of the reaction mixture after 24 h was not 
possible by 1H NMR spectroscopy, and mass spectrometry of the solution was 
inconclusive, suggesting that multiple products are forming, some of which may be 
unstable under such conditions. 




1H NMR spectra for the reaction of [(6-p-cymene)Ru(6-
aspartame)](OTf)2 (3) with ascorbate at pH 7.04, 310 K at times (A) 0 h, (B) 8 h, (C) 
16 h and (D) 24 h, showing how the peaks for the aliphatic protons of the complex 
change with time. Peaks b – e decrease in intensity. Signals for all aromatic protons 
appear in the region between 7.1 ppm and 7.2 ppm, which decrease by ca. 35% over 
24 h. Peaks corresponding to ascorbate are labelled (*). No new peaks appear over 
the timescale investigated. Peak x is unassigned. 
2+ 
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Figure 4.10  Decrease in intensity with time of signal at 3.08 ppm (c, Figure 4.9) of 
[(6-p-cymene)Ru(6-aspartame)]2+ (3) (100 M, 10 mM phosphate buffer, pH 7.04, 
D2O, 310 K) after addition of 10 mol equivalents ascorbate. The curve represents the 
computer best-fit for a pseudo-first-order reaction with a rate constant of 6.9 x 10-5    
s-1 (half-life 2.8 h). 
 
4.3.5 Cytotoxicity 
Complex 3 was non-toxic towards both the human ovarian A2780 and human lung 
A549 cancer cell lines at concentrations up to 100 µM, and therefore it is deemed 
inactive. 
 
4.3.6 Interaction with Sweet Taste Receptor 
Complexes 3 and 4 did not activate the sweet taste receptor up to concentrations of 1 
mM (the highest test concentration). Furthermore, the inability of 3 to bind to the 
same receptor site as aspartame was illustrated by the absence of any competitive 
effects in the FLIPR assay response to aspartame in the presence of excess ruthenium 
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complex. The responses of aspartame and the metal complexes at 0.1 mM in the 
assay are shown in Figure 4.11 and that of aspartame with the ruthenium complex in 
Figure 4.12. 
 































































































































Figure 4.11 Time dependent Ca2+-response of cells expressing the sweet taste 
receptor to application of (A) aspartame, (B) [(6-p-cymene)Ru(6-aspartame)]2+ (3) 
and (C) [(6-p-cymene)Os(6-aspartame)]2+ (4) (0.1 mM) recorded in the FLIPR 
assay. The increase in signal in (A) shows that aspartame stimulates the sweet taste 
receptor, whereas the metal complexes 3 and 4 are not able to stimulate the sweet 
taste receptor.  
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